

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : C07D 471/04, A61K 31/435		A2	(11) International Publication Number: <b>WO 00/11000</b>
			(43) International Publication Date: 2 March 2000 (02.03.00)
(21) International Application Number: PCT/SE99/01402 (22) International Filing Date: 18 August 1999 (18.08.99) (30) Priority Data: 9802794-9 21 August 1998 (21.08.98) SE (71) Applicant (for all designated States except US): ASTRA AKTIEBOLAG [SE/SE]; S-151 85 Södertälje (SE). (72) Inventors; and (75) Inventors/Applicants (for US only): AMIN, Kosrat [SE/SE]; Astra Hassle AB, S-431 83 Mölndal (SE). DAHLSTRÖM, Mikael [FI/SE]; Astra Hassle AB, S-431 83 Mölndal (SE). NORDBERG, Peter [SE/SE]; Astra Hassle AB, S-431 83 Mölndal (SE). STARKE, Ingemar [SE/SE]; Astra Hassle AB, S-431 83 Mölndal (SE). (74) Agent: ASTRA AKTIEBOLAG; Intellectual Property, Patents, S-151 85 Södertälje (SE).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> Without international search report and to be republished upon receipt of that report.	
(54) Title: NEW COMPOUNDS			
<div style="text-align: center;"> <p>(1)</p> </div>			
(57) Abstract  The present invention relates to novel compounds, and therapeutically acceptable salts thereof of formula (I), which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## NEW COMPOUNDS

## TECHNICAL FIELD

5 The present invention relates to novel compounds, and therapeutically acceptable salts thereof, which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases. In further aspects, the invention relates to compounds of the invention for use in therapy; to processes for preparation of such new compounds; to pharmaceutical compositions  
10 containing at least one compound of the invention, or a therapeutically acceptable salt thereof, as active ingredient; and to the use of the active compounds in the manufacture of medicaments for the medical use indicated above.

## 15 BACKGROUND ART


Substituted imidazo[1,2-a]pyridines, useful in the treatment of peptic ulcer diseases, are known in the art, e.g. from EP-B-0033094 and US 4,450,164 (Schering Corporation); from EP-B-0204285 and US 4,725,601 (Fujisawa Pharmaceutical Co.); from WO 9418199 and  
20 WO 9510518 (Byk Gulden Lomberg Chem.) and from publications by J. J. Kaminski et al. in the Journal of Medical Chemistry (vol. 28, 876-892, 1985; vol. 30, 2031-2046, 1987; vol. 30, 2047-2051, 1987; vol. 32, 1686-1700, 1989; and vol. 34, 533-541, 1991).

For a review of the pharmacology of the gastric acid pump (the H<sup>+</sup>, K<sup>+</sup>-ATPase), see Sachs  
25 et al. (1995) Annu. Rev. Pharmacol. Toxicol. 35: 277-305.

## DISCLOSURE OF THE INVENTION

It has surprisingly been found that compounds of the Formula I, which are substituted  
30 imidazopyridine derivatives, are effective as inhibitors of the gastrointestinal H<sup>+</sup>, K<sup>+</sup>-ATPase and thereby as inhibitors of gastric acid secretion.

In one aspect, the invention thus relates to compounds of the general Formula I:



I

5

or a pharmaceutically acceptable salt thereof, wherein

R<sup>1</sup> is

- (a) H,
- 10 (b) C<sub>1</sub>-C<sub>6</sub> alkyl,
- (c) C<sub>1</sub>-C<sub>6</sub> alkenyl,
- (d) CH<sub>2</sub>OH,
- (e) halogen, or
- (f) thiocyno

15

R<sup>2</sup> is

- (a) C<sub>1</sub>-C<sub>6</sub> alkyl,
- (b) hydroxyalkyl,
- (c) C<sub>1</sub>-C<sub>6</sub> alkoxy C<sub>1</sub>-C<sub>6</sub> alkyl,
- 20 (d) hydroxy C<sub>1</sub>-C<sub>6</sub> alkoxy C<sub>1</sub>-C<sub>6</sub> alkyl,
- (e) C<sub>1</sub>-C<sub>6</sub> alkylthio C<sub>1</sub>-C<sub>6</sub> alkyl,
- (f) cyano C<sub>1</sub>-C<sub>6</sub> alkyl,
- (g) halogenated C<sub>1</sub>-C<sub>6</sub> alkyl, or
- (h) aminocarbonyl C<sub>1</sub>-C<sub>6</sub> alkyl

25

R<sup>3</sup> is

- (a) H,  
(b) C<sub>1</sub>-C<sub>6</sub> alkoxy,  
(c) C<sub>1</sub>-C<sub>6</sub> alkyl,  
(d) halogen,  
5 (e) hydroxy C<sub>1</sub>-C<sub>6</sub> alkyl,  
(f) hydroxy C<sub>1</sub>-C<sub>6</sub> alkoxy,  
(g) C<sub>1</sub>-C<sub>6</sub> alkoxy C<sub>1</sub>-C<sub>6</sub> alkyl,  
(h) C<sub>1</sub>-C<sub>6</sub> alkoxy C<sub>1</sub>-C<sub>6</sub> alkoxy,  
(i) C<sub>1</sub>-C<sub>6</sub> alkoxycarbonyl,  
10 (j) C<sub>1</sub>-C<sub>6</sub> alkanoyl,  
(k) halogenated C<sub>1</sub>-C<sub>6</sub> alkyl,  
(l) NO<sub>2</sub>,  
(m) CN,  
(n) C<sub>1</sub>-C<sub>6</sub> sulfonyl,  
15 (o) C<sub>1</sub>-C<sub>6</sub> sulfinyl,  
(p) C<sub>1</sub>-C<sub>6</sub> alkylthio,  
(q) C<sub>1</sub>-C<sub>6</sub> alkylaminosulfonyl,  
(r) C<sub>1</sub>-C<sub>6</sub> (alkyl)<sub>2</sub>aminosulfonyl,  
(s) aminosulfonyl,  
20 (t) C<sub>1</sub>-C<sub>6</sub> alkylsulfonylamino,  
(u) C<sub>1</sub>-C<sub>6</sub> (alkylsulfonyl)<sub>2</sub>amino,  
(v) trifluoromethylsulfonylamino,  
(x) C<sub>1</sub>-C<sub>6</sub> alkylcarbonylamino,  
(y) C<sub>1</sub>-C<sub>6</sub> alkoxycarbonylamino, or  
25 (z) C<sub>1</sub>-C<sub>6</sub> aminocarbonylamino, optionally substituted by one or two C<sub>1</sub>-C<sub>6</sub> alkyl groups,

R<sup>4</sup> is

- (a) H,  
30 (b) C<sub>1</sub>-C<sub>6</sub> alkyl.


(c) halogenated C<sub>1</sub>-C<sub>6</sub> alkyl,

(d) C<sub>1</sub>-C<sub>6</sub> alkoxy, or

(e) halogen,

5 Ar is a with R<sup>5</sup>, R<sup>6</sup>, and/or R<sup>7</sup> substituted phenyl, thienyl, furanyl, naphthyl or pyridyl group.

X is



10 R<sup>5</sup> is

(a) H,

(b) C<sub>1</sub>-C<sub>6</sub> alkyl,

(c) C<sub>1</sub>-C<sub>6</sub> alkoxy,

(d) hydroxy,

15 (e) hydroxy C<sub>1</sub>-C<sub>6</sub> alkyl,

(f) hydroxy C<sub>1</sub>-C<sub>6</sub> alkoxy,

(g) halogenated C<sub>1</sub>-C<sub>6</sub> alkyl,

(h) halogenated C<sub>1</sub>-C<sub>6</sub> alkoxy,

(i) C<sub>1</sub>-C<sub>6</sub> alkoxy C<sub>1</sub>-C<sub>6</sub> alkyl,

20 (j) halogen,

(k) hydroxy C<sub>1</sub>-C<sub>6</sub> alkoxy C<sub>1</sub>-C<sub>6</sub> alkyl,

(l) CN,

(m) C<sub>1</sub>-C<sub>6</sub> alkoxycarbonyl,

(n) C<sub>1</sub>-C<sub>6</sub> alkoxycarbonyloxy,

25 (o) C<sub>1</sub>-C<sub>6</sub> alkylsulfonyloxy,

(p) trifluoromethylsulfonyloxy,

(q) C<sub>1</sub>-C<sub>6</sub> acyloxy C<sub>1</sub>-C<sub>6</sub> alkyl,


(r) C<sub>1</sub>-C<sub>6</sub> alkylsulfonyl C<sub>1</sub>-C<sub>6</sub> alkyl,

- (s) C<sub>1</sub>-C<sub>6</sub> alkylsulfinyl C<sub>1</sub>-C<sub>6</sub> alkyl,
- (t) C<sub>1</sub>-C<sub>6</sub> alkylthio C<sub>1</sub>-C<sub>6</sub> alkyl,
- (u) C<sub>1</sub>-C<sub>6</sub> alkoxycarbonylamino C<sub>1</sub>-C<sub>6</sub> alkyl,
- (v) aryl,

5 (x) amino C<sub>1</sub>-C<sub>6</sub> alkyl,


(y) NHC=OR<sup>12</sup>

(z) H or C<sub>1</sub>-C<sub>4</sub> alkyl substituted



-group

(aa) H or C<sub>1</sub>-C<sub>4</sub> alkyl substituted



-group. or

(ab) C<sub>1</sub>-C<sub>6</sub> alkyl sulfonyl amino

10

R<sup>6</sup> is

- (a) H,
- (b) C<sub>1</sub>-C<sub>6</sub> alkyl,
- (c) halogen,
- 15 (d) hydroxy C<sub>1</sub>-C<sub>6</sub> alkyl,
- (e) halogenated C<sub>1</sub>-C<sub>6</sub> alkyl,
- (f) halogenated C<sub>1</sub>-C<sub>6</sub> alkoxy,
- (e) C<sub>1</sub>-C<sub>6</sub> alkoxy C<sub>1</sub>-C<sub>6</sub> alkyl, or
- (f) CN

20

R<sup>7</sup> is

- (a) H,
- (b) C<sub>1</sub>-C<sub>6</sub> alkyl,
- 25 (c) C<sub>1</sub>-C<sub>6</sub> alkoxy,
- (d) halogen,
- (e) NO<sub>2</sub>,
- (f) halogenated C<sub>1</sub>-C<sub>6</sub> alkyl,

- (g) halogenated C<sub>1</sub>-C<sub>6</sub> alkoxy,
- (h) aryloxy, or
- (i) CN

5 R<sup>8</sup> is

- (a) H or
- (b) C<sub>1</sub>-C<sub>6</sub> alkyl

R<sup>12</sup> is

- 10 (a) C<sub>1</sub>-C<sub>6</sub> alkoxy,
- (b) C<sub>1</sub>-C<sub>6</sub> alkoxy C<sub>2</sub>-C<sub>4</sub> alkoxy,
- (c) NH<sub>2</sub>,
- (d) hydroxy C<sub>2</sub>-C<sub>4</sub> alkoxy,
- (e) C<sub>1</sub>-C<sub>6</sub> alkyl carbonyloxy C<sub>2</sub>-C<sub>4</sub> alkoxy,
- 15 (f) halogenated C<sub>2</sub>-C<sub>4</sub> alkoxy,
- (g) halogenated C<sub>1</sub>-C<sub>4</sub> alkyl,
- (h) hydroxy C<sub>1</sub>-C<sub>4</sub> alkyl,
- (i) C<sub>1</sub>-C<sub>6</sub> alkyl carbonyloxy C<sub>1</sub>-C<sub>4</sub> alkyl,
- (j) aryl,
- 20 (k) aryl C<sub>1</sub>-C<sub>4</sub> alkyl,
- (l) C<sub>1</sub>-C<sub>4</sub> sulfanyl C<sub>2</sub>-C<sub>4</sub> alkoxy,
- (m) C<sub>1</sub>-C<sub>4</sub> sulfinyl C<sub>2</sub>-C<sub>4</sub> alkoxy, or
- (n) C<sub>1</sub>-C<sub>4</sub> sulfonyl C<sub>2</sub>-C<sub>4</sub> alkoxy,

- 25 R<sup>5</sup> and R<sup>6</sup> are in the ortho positions relative to X  
R<sup>7</sup> is in the meta or para position relative to X

R<sup>5</sup> and R<sup>8</sup> may together form a hydroxy- or alkoxy- substituted 5- or 6- membered ring,  
provided that one of R<sup>3</sup> and R<sup>4</sup> ≠ H or halogen



provided also that at least one of  $R^5$ ,  $R^6$  and  $R^7 \neq H$

provided also that when  $R^5 = (y), (z), (aa)$  or  $(ab)$ , at least one of  $R^3$  and  $R^4 \neq H$

provided also that when  $R^1 = H$  or  $Cl$ ,  $XAr \neq OCH_2Ar$

provided also that when  $R^1 = H$ , halogen or  $CH_2OH$ , at least one of  $R^5$  and  $R^6$  is  $C_1-C_6$  alkyl

5 provided also that when  $R^2$  is  $CH_2OH$  or  $CH_2CN$ , at least one of  $R^5$  and  $R^6$  is  $C_1-C_6$  alkyl

The term "aryl" includes phenyl, naphthyl, thienyl, furyl, pyridyl or imidazolyl, optionally substituted by 1-3 substituentents selected from  $H$ ,  $C_1-C_6$  alkyl,  $C_1-C_6$  alkoxy, halogen or

10  $CF_3$

As used herein, the term " $C_1-C_6$  alkyl" denotes a straight or branched alkyl group having from 1 to 6 carbon atoms. Examples of  $C_1-C_6$  alkyl include methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, t-butyl and straight- and branched-chain pentyl and  
15 hexyl.

The term "halogen" includes fluoro, chloro, bromo and iodo.

The term "pyridyl" includes the 2-, 3-, and 4-isomers and the terms thienyl and furanyl  
20 include the 2-, and 3-isomers.

Both the pure enantiomers, racemic mixtures and unequal mixtures of the two enantiomers are within the scope of the invention. It should be understood that all the possible diastereomeric forms (pure enantiomers, racemic mixtures and unequal mixtures of two  
25 enantiomers) are within the scope of the present invention. Also included in the invention are derivatives of the compounds of the Formula I which have the biological function of the compounds of the Formula I.

Depending on the process conditions the end products of the Formula I are obtained either  
30 in neutral or salt form. Both the free base and the salts of these end products are within the scope of the present invention.

Acid addition salts of the new compounds may in a manner known *per se* be transformed into the free base using basic agents such as alkali or by ion exchange. The free base obtained may also form salts with organic or inorganic acids.

5

In the preparation of acid addition salts, preferably such acids are used which form suitable therapeutically acceptable salts. Examples of such acids are hydrohalogen acids such as hydrochloric acid, sulfuric acid, phosphoric acid, nitric acid, aliphatic, alicyclic, aromatic or heterocyclic carboxylic or sulfonic acids, such as formic acid, acetic acid, propionic  
 10 acid, succinic acid, glycolic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, maleic acid, hydroxymaleic acid, pyruvic acid, p-hydroxybenzoic acid, embonic acid, methanesulfonic acid, ethanesulfonic acid, hydroxyethanesulfonic acid, halogenbenzenesulfonic acid, toluenesulfonic acid or naphthalenesulfonic acid.

15 Preferred compounds according to the invention are those of the formula I wherein

$R^1$  is H,  $CH_3$ ,  $CH_2OH$ ;


$R^2$  is  $CH_3$ ,  $CH_2CH_3$ ,  $CH_2CH_2OH$ ,  $CH_2CH_2SCH_3$ ,  $CH_2CH_2OCH_3$  or  $CH_2CH_2CN$ ;

$R^3$  is H,  $CH_3$ ,  $CH_2CH_3$ , F, Cl, Br,  $OCH_3$ ,  $OCH_2CH_3$ ,  $CH_2OH$ ,  $CH_2CH_2OH$ ,  $OCH_2CH_2OH$ ,  $CH_2CH_2OCH_3$ ,  $OCH_2CH_2OCH_3$ ,  $C=OOCH_3$ ,  $C=OOCH_2CH_3$ ,  $C=OCH_3$ ,  $C=OCH_2CH_3$ ,

20  $C=OCH(CH_3)_2$  or  $C=OCH_2CH_2CH_3$ ,

$R^4$  is H,  $CH_3$ ,  $CH_2CH_3$ , F, Cl, Br,  $OCH_3$  or  $OCH_2CH_3$ ;

Ar is phenyl, thienyl, furyl or naphthyl;



$R^5$  is H,  $CH_3$ ,  $CH_2CH_3$ ,  $OCH_3$ , OH,  $CH_2OH$ ,  $CH_2OCH_3$ ,  $CH_2CH_2OH$ ,  $CH_2CH_2OCH_3$ ,

25  $OCH_2CH_2OH$ ,  $OC=OOCH_3$ ,  $OC=OCH_2CH_3$ ,  $OCHF_2$ ,  $OCF_3$ , F, Cl, Br, CN, phenyl,  $CH_2CH_2OC=OCH_3$ ,  $CH_2NHC=OOCH_3$  or  $CH_2NHC=OOCH_2CH_3$ ;

$R^6$  is H,  $CH_3$ ,  $CH_2CH_3$ ,  $CF_3$ ,  $OCF_3$ ,  $OCF_2H$ , F, Cl, Br, or  $CH_2OCH_3$ ;

$R^7$  is H, F, Cl, Br,  $OCF_2H$ , or  $OCF_3$ ;

$R^8$  is H or  $CH_3$ , or  $CH_2CH_3$ .

More preferred compounds according to the invention are those of the formula I wherein


$R^1$  is H,  $CH_3$  or  $CH_2OH$ ;

$R^2$  is  $CH_3$ ,  $CH_2CH_3$ ,  $CH_2OH$ ,  $CH_2SCH_3$ ,  $CH_2OCH_3$  or  $CH_2CN$ ;

5  $R^3$  is H,  $CH_3$ ,  $CH_2CH_3$ ,  $OCH_3$ ,  $OCH_3$ ,  $CH_2OH$ ,  $C=OOCH_3$ ,  $C=OOCH_2CH_3$ ,  $C=OCH_3$ ,  $C=OCH_2CH_3$ , or  $C=OCH_2CH_2CH_3$ ;

$R^4$  is H, or  $CH_3$ ;

Ar is phenyl, thienyl or furyl



$R^5$  is H,  $CH_3$ ,  $CH_2CH_3$ ,  $OCH_3$ , OH,  $CH_2OH$ ,  $CH_2OCH_3$ ,  $CH_2CH_2OH$ ,  $CH_2CH_2OCH_3$ ,  $OCH_2CH_2OH$ ,  $OC=OOCH_3$ ,  $OC=OCH_2CH_3$ ,  $OCHF_2$ ,  $OCF_3$ , F, Cl, Br, CN,  $CH_2CH_2OC=OCH_3$ ,  $CH_2NHC=OOCH_3$  or  $CH_2NHC=OOCH_2CH_3$

$R^6$  is H,  $CH_3$ ,  $CH_2CH_3$ ,  $CF_3$ ,  $OCF_3$ ,  $OCF_2H$ , F, Cl, Br or  $CH_2OCH_3$ ;

15  $R^7$  is H, F, Cl, Br,  $OCF_2H$ ,  $OCF_3$ ;

$R^8$  is H or  $CH_3$ .

### Preparation


20 The present invention also provides the following processes A, B, C, D, E or for the manufacture of compounds with the general Formula I.

### Process A

25 Process A for manufacture of compounds with the general Formula I comprises the following steps:


Compounds of the general Formula II

10



wherein  $X^1$  is  $NH_2$  or  $OH$ , and  $R^1$ ,  $R^2$ ,  $R^3$ , and  $R^4$  are as defined for Formula I, can be reacted with compounds of the general Formula III

5



wherein "Ar" is as defined for Formula I and Y is a leaving group, such as a halide, tosyloxy or mesyloxy, to the compounds of the Formula I.

10

It is convenient to conduct this reaction in an inert solvent, e.g. acetone, acetonitrile, dimethoxyethane, methanol, ethanol or dimethylformamide with or without a base. The base is e.g. an alkali metal hydroxide, such as sodium hydroxide and potassium hydroxide; an alkali metal carbonate, such as potassium carbonate and sodium carbonate; or an

15 organic amine, such as triethylamin.


### Process B

Process B for manufacture of compounds with the general Formula I, wherein X is  $NH$ ,

20 comprises the following steps:


Compounds of the general Formula IV

11




wherein  $R^1$ ,  $R^2$ ,  $R^3$  and  $R^4$  are as defined for Formula I, can be reacted with compounds of the general Formula V

5



wherein "Ar" are as defined for Formula I, in the presence of a Lewis acid e.g. zinc chloride to the compounds of the Formula VI

10




wherein  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$  and Ar are as defined for Formula I, whereupon the compounds of the general Formula VI are reduced e.g. by using sodium borohydride or sodiumcyanoborohydride to compounds of the general Formula I, wherein X is NH. The reactions can be carried out under standard conditions in an inert solvent e.g. methanol or ethanol.

15

### Process C

20 Process C for manufacture of compounds with the general Formula I, wherein  $R^1$  is  $\text{CH}_2\text{OH}$  or H comprises the following steps:

Compounds of the general Formula VII




5

wherein  $X^1$  is  $NH_2$  or  $OH$ ,  $R^2$ ,  $R^3$  and  $R^4$  are as defined for Formula I, can be reacted with compounds of the general Formula III



10

wherein Ar is as defined for Formula I and Y is a leaving group, such as a halide, tosyloxy or mesyloxy, to the compounds of the Formula VIII



15

wherein  $R^2$ ,  $R^3$ ,  $R^4$ , Ar and X is as defined for Formula I.

It is convenient to conduct this reaction in an inert solvent, e.g. acetone, acetonitrile, dimethoxyethane, methanol, ethanol or N,N-dimethylformamide with or without a base.

20 The base is e.g. an alkali metal hydroxide, such as sodium hydroxide and potassium

hydroxide; an alkali metal carbonate, such as potassium carbonate and sodium carbonate;  
or an organic amine, such as triethylamin.


Reduction of compounds of the general Formula VIII, e.g. by using lithium aluminium  
5 hydride in tetrahydrofuran or ether yields the compounds of the general Formula I wherein  
 $R^1$  is  $CH_2OH$ .

Hydrolysis of compounds of formula VIII, e.g. by using a base such as sodium hydroxide  
or an acid such as hydrochloric acid. After hydrolysis, decarboxylation in an inert solvent  
10 such as diphenylether gives the compounds of formula I wherein  $R^1$  is H.

#### Process D


Process D for manufacture of compounds with the general Formula I, wherein  $R^1$  is  
15  $CH_2OH$  and X is NH comprises the following steps:

Compounds of the Formula IX




20

$R^2$ ,  $R^3$ , and  $R^4$  is as defined for Formula I, can be reacted with compounds of the general  
Formula V




25

wherein Ar is as defined for Formula I, in the presence of a Lewis acid, e.g. zinc chloride to the compounds of the Formula X



5

wherein R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and Ar are as defined for Formula I, whereupon the compounds of the general Formula X are reduced, e.g. by using sodium borohydride or sodium cyano borohydride to compounds of the general Formula XI



10

wherein R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and Ar are as defined for Formula I. The reactions can be carried out under standard conditions in an inert solvent e.g. methanol or ethanol.

15 Reduction of compounds of the general Formula XI e.g. by using lithium aluminium hydride in tetrahydrofuran or ether yields the compounds of the general Formula I wherein R<sup>1</sup> is CH<sub>2</sub>OH and X is NH.


Hydrolysis of compounds of formula XI, e.g. by using a base such as sodium hydroxide or  
20 an acid such as hydrochloric acid. After hydrolysis, decarboxylation in an inert solvent such as diphenylether gives the compounds of formula I wherein R<sup>1</sup> is H.



*Process E*


Condensation of compounds of the general Formula XII

5



wherein  $R^3$ ,  $R^4$ , and Ar are as defined for Formula I, with  $\alpha$ -halocarbonyl intermediates of the general formula  $R^2\text{COCH}(\text{Z})\text{R}^1$  wherein Z is a leaving group Br or Cl, in an inert solvent e.g. acetonitrile or ethanol results in formation of compounds of the general Formula XIII wherein  $R^2$ ,  $R^3$ ,  $R^4$ , and Ar are as defined for Formula I

10

15 *Medical use*

In a further aspect, the invention relates to compounds of the formula I for use in therapy, in particular for use against gastrointestinal inflammatory diseases. The invention also provides the use of a compound of the formula I in the manufacture of a medicament for the inhibition of gastric acid secretion, or for the treatment of gastrointestinal inflammatory diseases.

20

The compounds according to the invention may thus be used for prevention and treatment of gastrointestinal inflammatory diseases, and gastric acid-related diseases in mammals including man, such as gastritis, gastric ulcer, duodenal ulcer, reflux esophagitis and  
5 Zollinger-Ellison syndrome. Furthermore, the compounds may be used for treatment of other gastrointestinal disorders where gastric antisecretory effect is desirable, e.g. in patients with gastrinomas, and in patients with acute upper gastrointestinal bleeding. They may also be used in patients in intensive care situations, and pre-and postoperatively to prevent acid aspiration and stress ulceration.

10

The typical daily dose of the active substance varies within a wide range and will depend on various factors such as for example the individual requirement of each patient, the route of administration and the disease. In general, oral and parenteral dosages will be in the range of 5 to 1000 mg per day of active substance.

15

#### *Pharmaceutical formulations*

In yet a further aspect, the invention relates to pharmaceutical compositions containing at least one compound of the invention, or a therapeutically acceptable salt thereof, as active  
20 ingredient.

The compounds of the invention can also be used in formulations together with other active ingredients, e.g. antibiotics, such as amoxicillin.

25 For clinical use, the compounds of the invention are formulated into pharmaceutical formulations for oral, rectal, parenteral or other mode of administration. The pharmaceutical formulation contains a compound of the invention in combination with one or more pharmaceutically acceptable ingredients. The carrier may be in the form of a solid, semi-solid or liquid diluent, or a capsule. These pharmaceutical preparations are a further  
30 object of the invention. Usually the amount of active compounds is between 0.1–95% by weight of the preparation, preferably between 0.1–20% by weight in preparations for

parenteral use and preferably between 0.1 and 50% by weight in preparations for oral administration.

In the preparation of pharmaceutical formulations containing a compound of the present invention in the form of dosage units for oral administration the compound selected may be mixed with solid, powdered ingredients, such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose derivatives, gelatin, or another suitable ingredient, as well as with disintegrating agents and lubricating agents such as magnesium stearate, calcium stearate, sodium stearyl fumarate and polyethylene glycol waxes. The mixture is then processed into granules or pressed into tablets.

Soft gelatin capsules may be prepared with capsules containing a mixture of the active compound or compounds of the invention, vegetable oil, fat, or other suitable vehicle for soft gelatin capsules. Hard gelatin capsules may contain granules of the active compound. Hard gelatin capsules may also contain the active compound in combination with solid powdered ingredients such as lactose, saccharose, sorbitol, mannitol, potato starch, corn starch, amylopectin, cellulose derivatives or gelatin.

Dosage units for rectal administration may be prepared (i) in the form of suppositories which contain the active substance mixed with a neutral fat base; (ii) in the form of a gelatin rectal capsule which contains the active substance in a mixture with a vegetable oil, paraffin oil or other suitable vehicle for gelatin rectal capsules; (iii) in the form of a ready-made micro enema; or (iv) in the form of a dry micro enema formulation to be reconstituted in a suitable solvent just prior to administration.

Liquid preparations for oral administration may be prepared in the form of syrups or suspensions, e.g. solutions or suspensions containing from 0.1% to 20% by weight of the active ingredient and the remainder consisting of sugar or sugar alcohols and a mixture of ethanol, water, glycerol, propylene glycol and polyethylene glycol. If desired, such liquid preparations may contain coloring agents, flavoring agents, saccharine and carboxymethyl cellulose or other thickening agent. Liquid preparations for oral administration may also be

prepared in the form of a dry powder to be reconstituted with a suitable solvent prior to use.

Solutions for parenteral administration may be prepared as a solution of a compound of the invention in a pharmaceutically acceptable solvent, preferably in a concentration from 0.1% to 10% by weight. These solutions may also contain stabilizing ingredients and/or buffering ingredients and are dispensed into unit doses in the form of ampoules or vials. Solutions for parenteral administration may also be prepared as a dry preparation to be reconstituted with a suitable solvent extemporaneously before use.

10

The compounds according to the invention can also be used in formulations together with other active ingredients, e.g. for the treatment or prophylaxis of conditions involving infection by *Helicobacter pylori* of human gastric mucosa. Such other active ingredients may be antimicrobial agents, in particular:

- 15 •  $\beta$ -lactam antibiotics such as amoxicillin, ampicillin, cephalothin, cefaclor or cefixime;
- macrolides such as erythromycin, or clarithromycin;
- tetracyclines such as tetracycline or doxycycline;
- aminoglycosides such as gentamycin, kanamycin or amikacin;
- quinolones such as norfloxacin, ciprofloxacin or enoxacin;
- 20 • others such as metronidazole, nitrofurantoin or chloramphenicol; or
- preparations containing bismuth salts such as bismuth subcitrate, bismuth subsalicylate, bismuth subcarbonate, bismuth subnitrate or bismuth subgallate.

### *Examples*

25

## EXAMPLES

### 1. PREPARATION OF COMPOUNDS OF THE INVENTION

#### *Example 1.1*

*Synthesis of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-6-methoxyimidazo[1,2-a]pyridine*

A mixture of 8-amino-6-methoxy-2,3-imidazo[1,2-a]pyridine (0.4 g, 2.09 mmol), 2,6-dimethylbenzylchloride (0.32 g, 2.07 mmol), sodium carbonate (0.4 g), potassium iodide (0.2 g) and acetonitrile (5 ml) was refluxed for 5 hours. The solvent was evaporated and the residue was purified by chromatography (methylene chloride:ethyl acetate, 70:30) yielding 250 mg (39 %) of the desired product.

Example 1.2-1.6, 1.9-1.16, 1.18-1.28, 1.30-1.40, 1.48-1.50 and 1.78-1.79 were prepared according to example 1.

*Example 1.2**Synthesis of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-6-nitroimidazo[1,2-a]pyridine*

Yield: 86 %

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.3 (s, 3H), 2.35 (s, 6H), 2.45 (s, 3H), 4.4 (d, 2H), 5.05 (bs, 1H), 6.9 (s, 1H), 7.05-7.15 (m, 3H), 8.4 (s, 1H)

*Example 1.3**Synthesis of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-6-trifluoromethylimidazo[1,2-a]pyridine*

Yield: 81 %

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.35 (s, 3H), 2.38 (s, 6H), 2.4 (s, 3H), 4.3 (d, 2H), 4.95 (bs, 1H), 6.25 (s, 1H), 6.75 (d, 2H), 7.6 (s, 1H)

*Example 1.4**Synthesis of 8-(2,6-dimethylbenzylamino)-2,3,5-trimethylimidazo[1,2-a]pyridine*

Yield: 52 %

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.3 (s, 3H), 2.4 (6H), 2.65 (s, 3H), 2.75 (s, 3H), 4.3 (d, 2H), 4.65 (bs, 1H), 6.05 (d, 1H), 6.3 (d, 1H) 6.95-7.15 (m, 3H)

*Example 1.5*

*Synthesis of 8-(2-methylbenzylamino)-2,3,6-trimethylimidazo[1,2-a]pyridine*

Yield: 60 %

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.25 (s, 3H), 3.32 (s, 3H), 2.36 (s, 3H), 2.38 (s, 3H), 4.38 (d, 2H), 5.20 (t, 1H), 5.93 (s, 1H), 7.02 (s, 1H), 7.17-7.33 (m, 4H)

*Example 1.6*

*Synthesis of ethyl 8-(2,6-dimethylbenzylamino) -2,3-dimethylimidazo[1,2-a]pyridine-6-carboxylate*

Yield:37%

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 1.45 (t, 3H), 2.35 (s, 3H), 2.4 (s, 6H), 2.45 (s, 3H), 4.4-4.5 (m, 4H), 4.85 (bs, 1H), 6.75 (s, 1H), 7.05-7.15 (m, 3H), 8.05 (s, 1H)

*Example 1.7*

*Synthesis of 8-(4-methoxy-2,6-dimethylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridine*

8-amino-2,3-dimethylimidazo[1,2-a]pyridine (0.5 g, 3.1 mmol), 4-methoxy-2,6-dimethylbenzaldehyd (0.51 g, 3.11 mmol) were dissolved in methanol (10 ml) whereupon zinc chloride (0.51 g, 3.82 mmol) dissolved in methanol (5 ml) was added. Sodium cyanoborohydride was added in portions and the mixture was refluxed for 3 h under nitrogen. The mixture was stirred at 0-5 °C and 1 M sodium hydroxide (20ml) was added. After extraction with 2x 50 ml of methylene chloride the combined organic layer was washed with water and dried over sodium sulfate. The solvent was removed under reduced pressure. The residue was chromatographed on

silica (dichloromethane: ethyl acetate, 1:1) yielding 0.58 g 60 % of the title compound.

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.35 (s, 12H), 3.79 (s, 3H), 4.27 (d, 2H), 4.75 (t, 1H), 6.19 (d, 1H), 6.59 (s, 2H), 6.69-6.75 (m, 1H), 7.24 (d, 1H)

Example 1.8, 1.17 and 1.41- 1.45 were prepared according to Example 7.

*Example 1.8*

*Synthesis of 8-[(2,6-bismethoxymethyl)benzylamino]- 2,3,6-trimethylimidazo[1,2-a]pyridine*

Yield: 54 %

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.25 (s, 3H), 2.3 (s, 6H), 3.35 (s, 6H), 4.45 (d, 2H), 4.5 (s, 4H), 4.95 (bs, 1H), 6.15 (s, 1H), 7.0 (s, 1H), 7.2-7.35(m, 3H)

Example 1.9-1.28 were prepared according to Example 1.1

*Example 1.9*

*Synthesis of 8-(2,6-dimethylbenzylamino)-3-fluoro-2-methylimidazo[1,2-a]pyridine*

Yield: 33 %

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.3 (s,3H), 2.35 (s, 6H), 4.3 (d, 2H), 4.8 (bs, 1H), 6.15 (d, 1H), 6.7 (t, 1H), 6.95-7.15 (m, 3H), 7.25 (d, 1H)

*Example 1.10*

*Synthesis of 3-chloro-8-(2,6-dimethylbenzylamino)-2-methylimidazo[1,2-a]pyridine*

Yield: 0.6 %

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.4 (s, 6H), 2.45 (s, 3H), 4.35 (d, 2H), 4.8 (bs, 1H), 6.3 (d, 1H), 6.8 (t, 1H), 7.05-7.15 (m, 3H), 7.5 (d, 1H)

*Example 1.11*

*Synthesis of 2,3-dimethyl-8-(2-phenylbenzylamino)-imidazo[1,2-a]pyridine*

Yield: 15 %

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.35 (s, 3H), 2.4 (s, 3H), 4.35 (d, 2H), 5.35 (t, 1H), 5.85 (d, 1H), 6.55 (t, 1H), 7.20 (d, 1H), 7.25- 7.4 (m, 8H), 7.55 (m, 1H)

*Example 1.12*

*Synthesis of 2,3-dimethyl-8-[(2,4-dimethyl-3-furyl)methylamino]-imidazo[1,2-a]pyridine*

Yield: 4 %

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 1.95 (s, 3H), 2.25 (s, 3H), 2.35 (s, 3H), 2.4 (s, 3H), 4.1 (d, 2H), 4.9 (bs, 1H), 6.15 (d, 1H), 6.7 (t, 1H), 7.05 (s, 1H), 7.25 (d, 1H)

*Example 1.13*

*Synthesis of 2,3-dimethyl-8-[(2-methyl-1-naphthyl)methylamino]-imidazo[1,2-a]pyridine hydrochloride*

5 Yield: 24 %

<sup>1</sup>H-NMR (300 MHz, DMSO): δ 2.35 (s, 3H), 2.45 (s, 3H), 2.6 (s, 3H), 4.8 (d, 2H), 6.6 (bs, 1H), 7.15 (d, 1H), 7.35-7.55 (m, 4H), 7.8-8.1 (m, 4H)

10 *Example 1.14*

*Synthesis of 8-[(1-bromo-2-naphthyl)methylamino]-2,3-dimethylimidazo[1,2-a]pyridine*



Yield: 21 %

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.3 (s, 3H), 2.4 (s, 3H), 4.8 (d, 2H), 5.8 (t, 1H), 5.95 (d, 1H), 6.55 (t, 1H), 7.2 (d, 1H), 7.45-7.6 (m, 3H), 7.68 (d, 1H), 7.77 (d, 1H), 8.33 (d, 1H)

*Example 1.15*

*Synthesis of 8-(2-ethoxycarbonyl-6-methylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridine*

Yield: 5 %

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 1.25 (t, 3H), 2.35 (s, 6H), 2.45 (s, 3H), 4.25 (q, 2H), 4.55 (d, 2H), 5.1 (bs, 1H), 6.2 (d, 1H), 6.7 (t, 1H), 7.2-7.35 (m, 3H), 7.65 (d, 1H)

*Example 1.16*

*Synthesis of 8-(2-methoxy-6-methylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridine*

Yield: 39 %

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.35 (s, 6H), 2.4 (s, 3H), 3.8 (s, 3H), 4.4 (d, 2H), 4.9 (bs, 1H), 6.25 (d, 1H), 6.7-6.85 (m, 3H), 7.15 (d, 1H), 7.2 (d, 1H)

Example 1.17 was prepared according to example 1.7

*Example 1.17*

*Synthesis of 8-(2-methoxymethyl-6-methylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridine*

Yield: 52 %

<sup>1</sup>H-NMR (500 MHz, CDCl<sub>3</sub>): δ 2.34 (s, 3H), 2.35 (s, 3H), 2.40 (s, 3H), 3.36 (s, 3H), 4.40 (d, 2H), 4.50 (s, 2H), 4.86 (t, 1H), 6.24 (d, 1H), 6.71-6.74 (m, 1H), 7.15-7.21 (m, 3H), 7.25 (d, 1H)

5

*Example 1.18**Synthesis of 8-(2,6-dichlorobenzylamino)-2,3-dimethylimidazo[1,2-a]pyridine*

Yield: 49 %

10

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.35 (s, 3H), 2.4 (s, 3H), 4.7 (d, 2H), 5.2 (bs, 1H), 6.3 (d, 1H), 6.7 (t, 1H), 7.1-7.4 (m, 4H)

*Example 1.19*15 *Synthesis of 8-(2,6-dibromobenzylamino)-2,3-dimethylimidazo[1,2-a]pyridine*

Yield: 70 %

20

<sup>1</sup>H-NMR (500 MHz, CDCl<sub>3</sub>): δ 2.45 (s, 3H), 2.48 (s, 3H), 4.7 (d, 2H), 5.15 (bs, 1H), 6.3 (d, 1H), 6.7 (t, 1H), 7.0 (t, 1H), 7.25 (d, 1H), 7.55 (d, 2H)

*Example 1.20**Synthesis of 2,3-dimethyl-8-(2-trifluoromethoxybenzylamino)-imidazo[1,2-a]pyridine hydrochloride*

25

Yield: 51 %

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.3 (s, 6H), 2.4 (s, 6H), 4.55 (d, 2H), 5.7 (t, 1H), 5.95 (d, 1H), 6.5 (t, 1H), 7.1-7.3 (m, 4H), 7.45 (d, 1H)

30

*Example 1.21*

*Synthesis of 2,3-dimethyl-8-(2-fluoro-6-trifluoromethylbenzylamino)-imidazo[1,2-a]pyridine hydrochloride*

5     Yield: 36 %

<sup>1</sup>H-NMR (300 MHz, DMSO-d<sub>6</sub>): δ 2.4 (s, 3H), 2.45 (s, 3H), 4.55 (d, 2H), 6.85 (bs, 1H), 7.05 (d, 1H), 7.35 (t, 1H), 7.7 (bs, 3H), 8.0 (d, 1H)

10     *Example 1.22*

*Synthesis of 2-([(2,3-dimethylimidazo[1,2-a]pyridin-8-yl)amino]methyl)phenyl acetate methanesulfonate*

Yield: 58%

15

<sup>1</sup>H-NMR (600 MHz, CDCl<sub>3</sub>): δ 2.04 (s, 3H), 2.43 (s, 3H), 2.57 (s, 3H), 2.68 (s, 3H), 3.08 (t, 2H), 4.31 (t, 2H), 4.60 (s, 2H), 6.47 (d, 1H), 7.03-7.06 (m 1H), 7.18-7.40 (m, 2H), 7.23-7.24 (m, 2H), 7.38-7.40 (m, 2H), 7.45 (bs, 1H), 14.64 (s, 1H)

20     *Example 1.23*

*Synthesis of 8-(2-ethylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridine*

Yield: 36 %

25

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 1.27 (t, 3H), 2.35 (s, 3H), 2.39 (s, 3H), 2.74 (q, 2H), 4.44 (d, 2H), 5.30 (t, 1H), 6.06 (d, 1H), 6.60-6.66 (m, 1H), 7.10-7.30 (m, 5H), 7.37 (d, 1H)

*Example 1.24*

*Synthesis of 8-[1-(2,6-dimethylphenyl)ethylamino]-2,3-dimethylimidazo[1,2-a]pyridine*

30

Yield: 16 %

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 1.65 (d, 3H), 2.3 (s, 3H), 2.4 (s, 3H), 2.45 (s, 6H), 5.0 (m, 1H), 5.4 (d, 1H), 5.55 (d, 1H), 6.45 (t, 1H), 6.9-7.05 (m, 3H), 7.1 (d, 1H)

5

*Example 1.25*

*Synthesis of 8-[1-(2,6-dimethylphenyl)ethoxy]-2,3-dimethylimidazo[1,2-a]pyridine*

Yield: 24 %

10

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 1.8 (d, 3H), 2.35 (s, 3H), 2.45 (s, 3H), 2.5 (s, 6H), 5.8 (q, 1H), 5.95 (d, 1H), 6.45 (d, 1H), 6.9-7.0 (m, 3H), 7.30 (d, 1H)

*Example 1.26*

15 *Synthesis of 2,3-dimethyl-8-(2-[2-(methylsulfonyl)ethyl]-benzylamino)-imidazo[1,2-a]pyridine*

Yield: 34 %

20 <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.34 (s, 6H), 2.67 (s, 3H), 3.18-3.33 (m, 4H), 4.43 (d, 2H), 5.15 (t, 1H), 6.14 (d, 1H), 6.62-6.68 (m, 1H), 7.15-7.30 (m, 4H), 7.37 (d, 1H)

*Example 1.27*

25 *Synthesis of 8-(2-[2-(methylcarbonyloxy)ethyl]-4-fluoro-6-methylbenzylamino)-2,3-dimethyl-imidazo[1,2-a]pyridine*

Yield: 33 %

Example 1.30 and 1.31 are prepared from a mixture of 2-chloro-6-methylbenzylbromide and 3-chloro-2-methylbenzylbromide. The yields are referred to 8-amino-2,3-dimethyl-6-methylimidazo[1,2-a]pyridine.

5 *Example 1.30*

*Synthesis of 8-(2-chloro-6-methylbenzylamino)-2,3,6-trimethylimidazo[1,2-a]pyridine*

Yield: 34 %

10 <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.35 (s, 9H), 2.55 (s, 3H), 4.5 (d, 2H), 4.85 (bs, 1H), 6.1 (s, 1H), 7.05 (s, 1H), 7.1-7.3 (m, 3H)

*Example 1.31*

*Synthesis of 8-(3-chloro-2-methylbenzylamino)-2,3,6-methylimidazo[1,2-a]pyridine*

15

Yield: 27 %

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.25 (s, 3H), 2.35 (s, 3H), 2.4 (s, 3H), 2.45 (s, 3H), 4.4 (d, 2H), 5.25 (t, 1H), 5.85 (s, 1H), 7.0-7.1 (m, 2H), 7.25-7.35 (m, 2H)

20

Example 1.32 and 1.33 are prepared from a mixture of 2-bromo-6-methylbenzylbromide and 3-bromo-2-methylbenzylbromide. The yields are referred to 8-amino-2,3-dimethylimidazo[1,2-a]pyridine.

25 *Example 1.32*

*Synthesis of 8-(2-bromo-6-methylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridine*

Yield: 25 %

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.01 (s, 3H), 2.33 (s, 3H), 2.35 (s, 3H), 2.37 (s, 3H), 3.00 (t, 2H), 4.25 (t, 2H), 4.31 (d, 2H), 4.78 (bs, 1H), 6.22 (d, 1H), 6.73 (t, 1H), 6.80 (d, 2H), 7.26 (d, 1H)

5 *Example 1.28*

*Synthesis of 8-(3-phenoxybenzylamino)-2,3-dimethylimidazo[1,2-a]pyridine*

Yield: 20 %

10 <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.3 (s, 3H), 2.4 (s, 3H), 4.4 (m, 2H), 5.5 (m, 1H), 6.0 (d, 1H), 6.55 (t, 1H), 6.85-7.35 (m, 10H)

*Example 1.29*

15 *Synthesis of 8-(2,6-dimethylbenzylamino)-2,3-dimethyl-7-nitroimidazo[1,2-a]pyridine*

2,3-dimethyl-8-(2,6-dimethylbenzylamino)-imidazo[1,2-a]pyridine (2.0 g, 7.16 mmol) was dissolved in acetic acid (30 ml) and nitric acid (0.53 g, 7.57 mmol) was added. The mixture was heated to 80-85 °C and stirred for 3 h at this temperature. After evaporation of the major part of the acetic acid, the residue was partitioned between methylene chloride and water. The organic layer was washed with a solution of sodium carbonate and the solvent was removed under reduced pressure. The residue was dissolved in methylene chloride (100 ml) and filtered through silica gel (10 g) whereupon the methylene chloride was removed under reduced pressure. Chromatography with methylene chloride (100%) gave  
25 0.4 g (17%) of the title compound.

Example 1.30-1.40 were prepared according to Example 1.1

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.35 (s, 6H), 2.45 (s, 3H), 4.55 (d, 2H), 4.85 (bs, 1H), 6.25 (d, 1H), 6.75 (t, 1H), 7.05-7.2 (m, 2H), 7.25 (d, 1H), 7.4 (d, 1H)

*Example 1.33*

5 *Synthesis of 8-(3-bromo-2-methylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridine*

Yield: 16 %

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.35 (s, 3H), 2.4 (s, 3H), 2.45 (s, 3H), 4.45 (d, 2H), 5.35  
10 (bs, 1H), 6.0 (d, 1H), 6.65 (t, 1H), 7.0 (t, 1H), 7.2-7.35 (m, 3H), 7.5 (d, 1H)

Example 1.34 and 1.35 are prepared from a mixture of 2-chloro-6-methylbenzylbromide and 3-chloro-2-methylbenzylbromide. The yields are referred to 8-amino-2,3-dimethylimidazo[1,2-a]pyridine.

15

*Example 1.34*

*Synthesis of 8-(2-chloro-6-methylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridine*

Yield: 24 %

20

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.35 (s, 6H), 2.45 (s, 3H), 4.5 (d, 2H), 4.85 (bs, 1H), 6.25 (d, 1H), 6.7 (t, 1H), 7.1-7.35 (m, 4H)

*Example 1.35*

25 *Synthesis of 8-(3-chloro-2-methylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridine*

Yield: 19 %

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.35 (s, 3H), 2.4 (s, 3H), 2.45 (s, 3H), 4.45 (d, 2H), 5.3 (t,  
30 1H), 6.0 (d, 1H), 6.6 (t, 1H), 7.05 (t, 1H), 7.25-7.35 (m, 3H)

*Example 1.36**Synthesis of 8-(2-chloro-4,6-dimethylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridine*

Yield: 7 %

5

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.28 (s, 3H), 2.34 (s, 6H), 2.38 (s, 3H), 4.46 (d, 2H), 4.86 (t, 1H), 6.22 (d, 1H), 6.28-6.74 (m, 1H), 6.90 (s, 1H), 7.07 (s, 1H), 7.25 (d, 1H)

*Example 1.37*10 *Synthesis of 8-(2,4-dichloro-6-methylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridine*

Yield: 28 %

15 

<sup>1</sup>H-NMR (500 MHz, CDCl<sub>3</sub>): δ 2.34 (s, 3H), 2.35 (s, 3H), 2.41 (s, 3H), 4.46 (d, 2H), 4.86 (t, 1H), 6.21 (d, 1H), 6.69-6.72 (m, 1H), 7.10 (d, 1H), 7.24-7.28 (m, 2H)

*Example 1.38**Synthesis of 8-(2-cyano-6-methylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridine*

20

Yield: 49 %

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.35 (s, 6H), 2.45 (s, 3H), 4.6 (d, 2H), 4.95 (bs, 1H), 6.25 (d, 1H), 6.7 (t, 1H), 7.25-7.35 (m, 2H), 7.4 (d, 1H), 7.55 (d, 1H)

25

*Example 1.39**Synthesis of 8-(3-cyano-2-methylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridine*

30 Yield: 26 %



<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.35 (s, 3H), 2.4 (s, 3H), 2.6 (s, 3H), 4.45 (d, 2H), 5.35 (t, 1H), 5.95 (d, 1H), 6.65 (t, 1H), 7.2-7.3 (m, 2H), 7.55 (t, 2H)

5

*Example 1.40*

*Synthesis of 8-(3-difluoromethoxybenzylamino)-2,3-dimethylimidazo[1,2-a]pyridine hydrochloride*

10 Yield: 45 %

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.25 (s, 3H), 2.35 (s, 3H), 4.5 (d, 2H), 5.65 (t, 1H), 5.95 (d, 1H), 6.5 (d, 1H), 6.55 (t, 1H), 7.0-7.25 (m, 4H), 7.4 (d, 1H)

15 Example 7 41- 45 were prepared according to Example 7.

*Example 1.41*

*Synthesis of 8-(2-methoxymethyl-6-methylbenzylamino) -2,3,6-trimethylimidazo[1,2-a]pyridine*

20

Yield: 60 %

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.25 (s, 3H), 2.3 (s, 6H), 2.4 (s, 3H), 3.35 (s, 3H), 4.4 (d, 1H), 4.5 (s, 3H), 4.85 (bs, 1H), 6.1 (s, 1H), (7.0 s, 1H), 7.05-7.2 (m, 3H)

25

*Example 1.42*

*Synthesis of 8-(2,6-dimethyl-3-nitrobenzylamino)-2,3-dimethylimidazo[1,2-a]pyridine*

Yield: 15 %

30

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.32 (s, 3H), 2.35 (s, 3H), 2.45 (s, 3H), 2.5 (s, 3H), 4.4 (d, 2H), 4.75 (m, 1H), 6.22 (d, 1H), 6.75 (t, 1H), 7.17 (d, 1H), 7.3 (d, 1H), 7.7 (d, 1H)

*Example 1.43*

5 *Synthesis of 2,3-dimethyl-8-[2-(2-methoxyethyl)-6-methylbenzylamino]-6-methylimidazo[1,2-a]pyridine hydrochloride*

Yield: 11 %

10 <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.35 (s, 3H), 2.38 (s, 3H), 2.44 (s, 3H), 2.46 (s, 3H), 3.02 (t, 2H), 3.30 (s, 3H), 3.59 (t, 2H), 4.41 (s, 2H), 6.46 (s, 1H), 7.10-7.35 (m, 4H)

*Example 1.44*

*Synthesis of 8-[2,6-dimethylbenzylamino]-2,3,7-trimethylimidazo[1,2-a]pyridine*  
15 *hydrochloride*

Yield: 11 %

20 <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.35 (s, 9H), 2.4 (s, 3H), 2.6 (s, 3H), 4.65 (s, 2H), 6.95-7.15 (m, 4H), 7.5 (bs, 1H), (neutral form)

*Example 1.45*

*Synthesis of 2,3-dimethyl-8-[(2,4-dimethyl-3-thienyl)methylamino]-imidazo[1,2-a]pyridine*

25 Yield: 44 %

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.2 (s, 3H), 2.35 (s, 3H), 2.36 (s, 3H), 2.45 (s, 3H), 4.2 (d, 2H), 4.8 (bs, 1H), 6.2 (d, 1H), 6.65-6.75 (d, 2H), 7.25 (d, 1H)

30 *Example 1.46*

*Synthesis of 2,6-dimethyl-3-hydroxymethyl-8-(2-methoxymethyl-6-methylbenzylamino)-imidazo[1,2-a]pyridine*

Lithium aluminium hydride (0.29 g, 7.7 mmol) was added to tetrahydrofuran (30 ml) and 3-carbethoxy-8-(2-methoxymethyl-6-methylbenzylamino)-2-methylimidazo[1,2-a]pyridine (1.4 g, 3.8 mmol) dissolved in tetrahydrofuran (30 ml) was added dropwise during 80 min. at room temperature and stirred for 4 h. Water (0.29 ml) was added dropwise, followed by sodium hydroxide (15%, 0.29 ml) and finally 0.93 ml of water. After stirring 30 min. the solids were filtered off and washed thoroughly with tetrahydrofuran. The solvent was removed under reduced pressure and chromatography on silica gel (methylene chloride:methanol, 9:1) gave (0.97 g 75 %) of the title compound as a white solid.

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.0 (s, 3H), 2.3 (s, 3H), 2.4 (s, 3H), 3.35 (s, 3H), 3.6 (bs, 1H) 4.4 (d, 2H), 4.5 (s, 2H), 4.6 (s, 2H), 4.9 (bs, 1H), 6.15 (s, 3H), 7.1-7.25 (m, 3H), 7.35 (s, 1H)

Example 1.47 was prepared according to Example 1.46

*Example 1.47*

*Synthesis of 8-(2-chloro-6-methylbenzylamino)-2,6-dimethyl-3-hydroxymethylimidazo[1,2-a]pyridine*

Yield: 46 %

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.25 (s, 3H), 2.3 (s, 3H), 2.45 (s, 3H), 4.5 (d, 2H), 4.8 (s, 2H), 4.85 (bs, 1H), 6.2 (s, 1H), 7.1-7.25 (m, 3H), 7.4 (s, 1H)

Example 1.48-1.49 were prepared according to Example 1.1

*Example 1.48*

*Synthesis of 8-(2,6-dimethylbenzylamino)-2-methylimidazo[1,2-a]pyridine*

Yield: 70 %

5 <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.35 (s, 9H), 4.3 (d, 2H), 4.8 (bs, 1H), 6.2 (d, 1H), 6.65 (t, 1H), 7.0-7.15 (m, 3H), 7.25 (s, 1H), 7.45 (d, 1H)

*Example 1.49*

*Synthesis of 8-(4-fluoro-2,6-dimethylbenzylamino)-2-methylimidazo[1,2-a]pyridine*

10

Yield: 71 %

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.35 (s, 6H), 2.4 (s, 3H), 4.3 (d, 2H), 4.75 (bs, 1H), 6.2 (d, 1H), 6.65 (t, 1H), 6.75 (d, 2H), 7.25 (s, 1H), 7.5 (d, 1H)

15

*Example 1.51*

*Synthesis of 2,6-dimethyl-8-(4-fluoro-2,6-dimethylbenzylamino)-imidazo[1,2-a]pyridine*

A mixture of 8-(4-fluoro-2,6-dimethylbenzylamino)-2-methyl-6-methylimidazo[1,2-a]pyridine 3-carboxylic acid (0.35 g, 1.03 mmol) and diphenyl ether and refluxed for 10  
20 min. Petroleum ether 40-60 was added at room temperature followed by hydrogen chloride in diethyl ether. The petroleum ether diphenylether layer was removed from the formed precipitate. The precipitate was washed with petroleum ether thereafter dissolved in methylene chloride and basified with sodium hydroxide (2M). The layers were separated  
25 and the organic layer was washed with water. The solvent was evaporated and the residue was chromatographed (hexane:ethyl acetate, 2:1) giving 0.17 g (50 %) of the title compound.

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.25 (s, 1H), 2.35 (s, 9H), 4.25 (d, 2H), 4.75 (bs, 1H), 6.05  
30 (s, 1H), 6.75 (d, 2H), 7.1 (s, 1H), 7.25 (s, 1H)

Example 1.52 were prepared according to example 1.51

*Example 1.52*

*Synthesis of 2,6-dimethyl-8-(2,6-dimethylbenzylamino)-imidazo[1,2-a]pyridine*

5

Yield: 40 %

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.25 (s, 1H), 2.35 (s, 3H), 2.4 (s, 6H), 4.3 (d, 2H), 4.75 (bs, 1H), 6.05 (s, 1H), 6.95-7.15, (m, 4H), 7.2 (s, 1H)

10

*Example 1.53*

*Synthesis of 8-(2,6-dimethylbenzylamino)-3-ethyl-2-methylimidazo[1,2-a]pyridine hydrochloride*

15 To a stirred mixture of 1-[8-(2,3-dimethylbenzylamino)-2-methylimidazo[1,2-a]pyridine-3-yl]-1-ethanol (0.3 g, 0.98 mmol), boron trifluoride diethyl etherate (0.14 ml, 3.2 mmol) in tetrahydrofuran (10 ml) was added sodium cyanoborohydride (0.13 g, 2.0 mmol). The reaction mixture was stirred for 2.5 h and the solvent was evaporated under reduced pressure. The residue was solved in methylene chloride and was washed twice with a  
20 saturated sodium bicarbonate solution. The organic layer was separated, dried and evaporated under reduced pressure. Purification twice by column chromatography on silica gel using 1) methylene chloride: ethyl acetate (100:7) 2) methylene chloride:methanol (100:3) as eluent and treating with HCl/diethyl ether gave 0.1 g (31%) of the title compound.

25

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 1.2 (t, 1H), 2.35 (s, 3H), 2.4 (s, 6H), 2.85 (q, 2H), 4.35 (d, 2H), 4.8 (bs, 1H), 6.2 (d, 1H), 6.7 (t, 1H), 7.05-7.15 (m, 3H), 7.35 (d, 1H)

*Example 1.54*

30 *Synthesis of 8-(2,6-dimethylbenzylamino)-2-methyl-3-vinylimidazo[1,2-a]pyridine*

A mixture of 1-[8-(2,3-dimethylbenzylamino)-2-methylimidazo[1,2-a]pyridine-3-yl]-1-ethanol (0.2 g, 0.65 mmol) and p-toluenesulfonic acid (0.029 g, 0.15 mmol) in benzene (40 ml) was refluxed for 20 h with Dean-Stark water separation. The solvent was  
5 evaporated under reduced pressure, the residue was solved in methylene chloride and washed with saturated sodium bicarbonate solution. The organic layer was separated, dried and evaporated under reduced pressure. Purification of the residue by column chromatography on silica gel using methylene chloride: ethyl acetate (10:1) gave 0.062 g (33%) of the title compound.

10

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.4 (s, 6H), 2.5 (s, 3H), 4.35 (d, 2H), 4.85 (bs, 1H), 5.35 (d, 1H), 5.55 (d, 1H), 6.25 (d, 1H), 6.75-6.85 (m, 2H), 7.05-7.15 (m, 3H), 7.6 (d, 1H)

*Example 1.55*

15 *Synthesis of 2-cyanomethyl-8-(2,6-dimethylbenzylamino)-3-methylimidazo[1,2-a]pyridine*

2-chloromethyl-8-(2,6-dimethylbenzylamino)-3-methylimidazo[1,2-a]pyridine (2.4 mmol) and potassium cyanide (2.4 mmol) were added to dimethyl sulfoxide (25 ml) and stirred for 2 h. at room temperature. Methylene chloride and water were added to the reaction  
20 mixture and the organic layer was separated, dried (Na<sub>2</sub>SO<sub>4</sub>) and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel using methylene chloride:methanol (10:1) as eluent. Crystallization from acetonitrile gave 0.25 g (34 %) of the title compound.

25 <sup>1</sup>H-NMR (500 MHz, CDCl<sub>3</sub>): δ 2.4 (s, 6H), 2.45 (s, 3H), 3.8 (s, 2H), 4.35 (d, 2H), 4.8 (bs, 1H), 6.3 (d, 1H), 6.8 (t, 1H), 7.1 (d, 2H), 7.15 (t, 1H), 7.3 (t, 1H)

*Example 1.56*

30 *Synthesis of 8-(2,6-dimethylbenzylamino)-3-methyl-2-methylsulfanylmethyl-imidazo[1,2-a]pyridine*

2-chloromethyl-8-(2,6-dimethylbenzylamino)-3-methylimidazo[1,2-a]pyridine (0.2 g, 0.64 mmol) and sodium methanethiolate (0.1 g, 1.3 mmol) were added to acetonitrile (10 ml)

and stirred for 4 h. at room temperature. The solvent was evaporated under reduced pressure and to the residue were added methylene chloride and water. The organic layer was separated, dried (Na<sub>2</sub>SO<sub>4</sub>) and evaporated under reduced pressure. Purification of the residue by column chromatography on silica gel using diethyl ether:petroleum ether (1:2) as eluent and crystallization from diethyl ether:petroleum ether (1:2) gave 0.05 g (24%) of the desired product.

<sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): δ 2.1 (s, 3H), 2.4 (s, 6H), 2.45 (s, 3H), 3.85 (s, 2H), 4.4 (s, 2H), 4.9 (bs, 1H), 6.25 (d, 1H), 6.75 (t, 1H), 7.1 (d, 2H), 7.15 (t, 1H), 7.3 (d, 1H)

10

#### *Example 1.57*

#### *Synthesis of 8-(2,6-dimethylbenzylamino)-2-methoxymethyl-3-methyl-imidazo[1,2-a]pyridine*

2-chloromethyl-8-(2,6-dimethylbenzylamino)-3-methylimidazo[1,2-a]pyridine (0.3 g, 0.96 mmol) was solved in methanol (20 ml) and stirred for 20 h. at room temperature and refluxed for 20 min. The solvent was evaporated under reduced pressure and the residue was dissolved in methylene chloride and washed with a bicarbonate solution. The organic layer was separated, dried (Na<sub>2</sub>SO<sub>4</sub>) and evaporated under reduced pressure. Purification of the residue by column chromatography on silica gel using diethyl ether:petroleum ether (2:1) as eluent and crystallization from diethyl ether:petroleum ether (2:1) gave 0.13 g (44%) of the desired product.

<sup>1</sup>H-NMR (500 MHz, CDCl<sub>3</sub>): δ 2.4 (s, 6H), 2.45 (s, 3H), 3.4 (s, 3H), 4.35 (d, 2H), 4.55 (s, 2H), 4.95 (bs, 1H), 6.25 (d, 1H), 6.8 (t, 1H), 7.05 (d, 2H), 7.15 (t, 1H), 7.3 (d, 1H)

25

#### *Example 1.58*

#### *Synthesis of 2-aminocarbonylmethyl-3-methyl-8-(2,6-dimethylbenzylamino)-7-imidazo[1,2-a]pyridine*

30

A mixture of Example 55 (40 mg, 0.13 mmol), potassium hydroxide (30 mg) in t-butanol 1.0 ml was refluxed for 10 minutes. The mixture was filtered and methylene chloride (2 ml) was added to the filtrate and washed with water. The organic layer was dried over sodium sulfate and evaporated giving 26 mg (64 %) of the title compound.

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.35 (s, 3H), 2.4 (s, 6H), 3.6 (s, 2H), 4.35 (d, 2H), 4.8 (bs, 1H), 5.55 (bs, 1H), 6.3 (d, 1H), 6.8 (t, 1H), 7.0-7.35 (m, 5H)

5 *Example 1.59*

*Synthesis of 8-(2-hydroxymethyl-6-methylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridine hydrochloride*

To an icecooled mixture of 2-(((2,3-dimethylimidazo[1,2-a]pyridin-8-yl)amino)methyl)-3-methylbenzoic acid (0.18 g, 0.59 mmol) in toluene (30 ml) was added dropwise Red-Al (5 ml) in toluene (7 ml) and was stirred at room temperature for 20 h. The mixture was cooled with ice and water (10 ml) and methylene chloride were added. After filtration the filtrate was evaporated under reduced pressure and the residue was purified by column chromatography on silica gel using methylene chloride:methanol (100:5) as eluent. The product was solved in methylene chloride/ether and treated with HCl/diethyl ether to give 0.024 g (12 %) of the title compound.

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.25 (s, 3H), 2.3 (s, 3H), 2.4 (s, 3H), 4.4 (d, 1H), 4.65 (s, 2H), 5.05 (bs, 1H), 6.25 (d, 1H), 6.75 (t, 1H), 7.1-7.25 (m, 4H)

20

*Example 1.60*

*Synthesis of 8-(2-methoxy-6-methylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridine*

8-(2-methoxy-6-methylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridine (0.14 g, 0.48 mmol) was solved in methylene chloride (9 ml) and the mixture was cooled to -73 °C. Boron tribromide in methylene chloride (1M) (2.37 ml, 2.37 mmol) was added dropwise and the mixture was stirred for 20 h. in a nitrogen atmosphere and the temperature was allowed to raise to room temperature. The reaction mixture was cooled on ice and ice, water and methylene chloride were added. The organic layer was separated, washed with saturated sodium bicarbonate, dried and evaporated under reduced pressure to give 0.077 g (57 %) of the title compound.

30



<sup>1</sup>H-NMR (500 MHz, CDCl<sub>3</sub>): δ 2.25 (s, 3H), 2.35 (s, 3H), 2.4 (s, 3H), 4.4 (d, 2H), 4.95 (t, 1H), 6.3 (d, 1H), 6.55 (d, 1H), 6.7 (t, 1H), 6.8 (d, 1H), 6.9 (t, 1H) 7.25 (d, 1H)

*Example 1.61*

5 *Synthesis of 8-(2-aminomethyl-6-methylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridine*

To a solution of 8-(2-cyano-6-methylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridine (0.42 g, 1.44 mmol) in ammonia saturated ethanol/methanol (10/2.5)(30 ml) was added Raney nickel (50 % in water)(0.45 g) The mixture was hydrogenated at room temperature and atmospheric pressure until the uptake of hydrogen ceased. Following filtration through  
10 celite, the solvents were evaporated under reduced pressure and the residue was purified by  
by column chromatography on silica gel using methylene chloride:methanol (10:2) as  
eluent. Recrystallization from methylene chloride/ diethyl ether gave 0.052 g (12%) of the  
desired product.

15

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.35 (s, 6H), 2.4 (s, 3H), 3.95 (s, 2H), 4.4 (s, 2H), 6.25 (d, 1H), 6.75 (t, 1H), 7.1-7.25 (m, 4H)

*Example 1.62*

20 *Synthesis of methyl N-(2-(((2,3-dimethylimidazo[1,2-a]pyridine-8-yl)amino)methyl)-3-methylbenzyl)carbamate*

To an ice cooled solution of 8-(2-aminomethyl-6-methylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridine (0.17 g, 0.58 mmol), pyridine (0.046 g, 0.58 mmol) in  
25 methylene chloride (8 ml) was added methyl chloroformate (0.055 g, 0.58 mmol) and the  
reacton mixture was stirred for 1.5 h. and the temperature was allowed to raise to 12  
°C. Methylene chloride was added and the solution was washed twice with water. The  
organic layer was separated, washed with saturated sodium bicarbonate, dried and  
evaporated under reduced pressure. The residue was purified by by column

chromatography on silica gel using methylene chloride:methanol (100:5) as eluent.

Recrystallization from diethyl ether gave 0.052 g (25 %) of the title compound.

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.35 (s, 6H), 2.45 (s, 3H), 3.55 (s, 3H), 4.4 (d, 2H), 4.45  
5 (d, 2H), 4.75 (bs, 1H), 5.25 (bs, 1H), 6.25 (d, 1H), 6.75 (t, 1H), 7.1-7.3 (m, 4H)

*Example 1.63*

*Synthesis of 2-(((2,3-dimethylimidazo[1,2-a]pyridine-8-yl)amino)methyl)-3-methylphenyl  
methyl carbonate hydrochloride*

10

A mixture of 8-(2-hydroxy-6-methylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridine  
(0.068 g, 0.24 mmol) sodium carbonate (0.12 g, 1.1 mmol), and potassium hydroxide  
(0.019 g, 0.34 mmol) in acetone (12 ml) was stirred for 15 min in room temperature in a  
nitrogen atmosphere. Methyl chloroformate (0.023 g, 0.24 mmol) was added and the  
15 reaction mixture was stirred for 70 min. Methylene chloride was added and the mixture  
was filtered and the filtrate was evaporated under reduced pressure. The residue was solved  
in methylene chloride, washed with saturated sodium bicarbonate and water and the  
organic layer was separated, dried and evaporated under reduced pressure. The residue was  
purified by column chromatography on silica gel using methylene chloride:methanol  
20 (100:5) as eluent and treated with HCl/diethyl ether to give 0.025 g (28 %) of the title  
compound.

25

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.35 (s, 3H), 2.5 (s, 3H), 2.6 (s, 3H), 3.9 (s, 3H), 4.5 (d,  
2H), 6.75 (d, 1H), 6.95-7.3 (m, 5H), 8.0 (t, 1H), 15.6 (bs, 1H)

*Example 1.64*

*Synthesis of 2-(2-(((2,3-dimethylimidazo[1,2-a]pyridin-8-yl)amino)methyl)-3-  
methylphenoxy)-1-ethanol*

To a solution of 8-(2-hydroxy-6-methylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridine (0.14 g, 0.5 mmol) in N,N-dimethylformamide (3 ml) was added lithium hydride (0.004 g, 0.51 mmol) and the mixture was stirred for 10 min at 100 °C. Ethylene carbonate (0.055 g, 0.63 mmol) was added and the mixture was stirred for 10 min at 130 °C.

5 Tetramethylammonium iodide (0.054 g, 0.63 mmol) was added and the mixture was stirred for 12 h. at 140-145 °C. The solvent was evaporated under reduced pressure and the residue was solved in methylene chloride, washed twice with saturated sodium bicarbonate. The organic layer was separated, dried and evaporated under reduced pressure and the residue was purified by column chromatography on silica gel using methylene  
10 chloride:methanol (100:6) as eluent to give 0.067 g (41 %) of the title compound.

<sup>1</sup>H-NMR (500 MHz, CDCl<sub>3</sub>): δ 2.3 (s, 3H), 2.35 (s, 3H), 2.45 (s, 3H), 4.0 (t, 2H), 4.15 (t, 2H), 4.5 (d, 2H), 6.25 (d, 1H), 6.35 (t, 1H), 6.7 (t, 1H), 6.75 (d, 1H), 6.8 (d, 1H), 7.1 (t, 1H), 7.2 (d, 1H)

15

#### *Example 1.65*

#### *Synthesis of 2-(((2,3-dimethylimidazo[1,2-a]pyridin-8-yl)amino)methyl)-3-methylphenyl trifluoromethanesulfonate*

20 To a solution of 8-(2-hydroxy-6-methylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridine (0.1 g, 0.32 mmol) in methylene chloride (7 ml) was added triethyl amine (0.07 g, 0.69 mmol) and the reaction mixture was cooled on ice. N,N-dimethylamino pyridine (0.077 g, 10 mmol) and trifluoromethanesulfonic anhydride (0.12 g, 0.41 mmol) in methylene chloride (0.5 ml) and N-phenyltrifluoromethanesulfonimide (0.28 g, 0.78 mmol) and  
25 potassium carbonate (0.38 g, 2.7 mmol) were added and the reaction mixture was stirred for 135 min. at 18 °C. Methylene chloride was added and the solution was washed with water/NH<sub>4</sub>Cl, saturated sodium bicarbonate and water. The organic layer was separated, dried, and evaporated under reduced pressure. Purification of the residue by column chromatography on silica gel using methylene chloride: ethyl acetate (10:2) as eluent and

crystallization from diethyl ether/petroleum ether gave 0.053 g (40 %) of the title compound.

<sup>1</sup>H-NMR (500 MHz, CDCl<sub>3</sub>): δ 2.33 (s, 3H), 3.35 (s, 3H), 2.45 (s, 3H), 4.45 (d, 2H), 5.0  
5 (bs, 1H), 6.25 (d, 1H), 6.75 (t, 1H), 7.15 (d, 1H), 7.2-7.35 (m, 3H)

*Example 1.66*

*Synthesis of 8-[2-(2-hydroxyethyl)benzylamino]-2,3-dimethylimidazo[1,2-a]pyridine*

10 A mixture of Example 22 (xCH<sub>3</sub>SO<sub>3</sub>H) (0.8 g, 1.85 mmol) and sodium hydroxide (0.2 g) were refluxed in ethyl alcohol for 3 hours. The solvent was evaporated and methylene chloride / water were added to the residue. The organic layer was dried over sodium sulfate and the solvent removed under reduced pressure. Trituration of the solid residue with diethyl ether gave 0.48 g ( 88 %) of the title compound.

15 <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.33 (s, 3H), 2.34 (s, 3H), 2.91 (t, 2H), 3.50 (bs, 1H), 3.87 (t, 2H), 4.40 (s, 2H), 5.63 (bs, 1H), 6.12 (d, 1H), 6.62-6.68 (m, 1H), 7.14-7.27 (m, 4H), 7.36 (d, 1H)

20 *Example 1.67*

*Synthesis of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-6-hydroxymethyl-imidazo[1,2-a]pyridine*

To a stirred solution of ethyl 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-imidazo[1,2-  
25 a]pyridine-6-carboxylate (1.2 g, 3.4 mmol) in tetrahydrofuran (30 ml) was added LiAlH<sub>4</sub> (0.7 g, 18.5 mmol) during 20 min. at 5 °C. 0.7 ml of water was added dropwise, followed by 0.7 ml of 15% sodium hydroxide and then 2.1 ml of water. The solids were removed by filtration and washed thoroughly with methylene chloride: methanol (1:1). The filtrate and washings were combined and the solvents were removed under reduced pressure. The  
30 residue was purified by column chromatography on silica gel using methylene chloride: methanol (10:1) as eluent. Treating the residue with diethyl ether and filtration gave 0.7 g (67%) of the title compound.

<sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): δ 2.35 (s, 6H), 2.4 (s, 6H), 4.35 (d, 2H), 4.65 (s, 2H), 4.9 (bs, 1H), 6.2 (s, 1H), 7.05-7.15 (m, 3H), 7.25 (s, 1H)

5 *Example 1.68*

*Synthesis of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-6-methoxymethyl-imidazo[1,2-a]pyridine hydrochloride*

To a stirred solution of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-6-hydroxymethyl-imidazo[1,2-a]pyridine (0.08 g, 0.26 mmol) in methylene chloride (5 ml) was added thionyl chloride (0.038 ml, 0.52 mmol) and the mixture was stirred for 2 h. A saturated bicarbonate solution was added and the organic layer was separated, dried (Na<sub>2</sub>SO<sub>4</sub>) and evaporated under reduced pressure. To the residue was added methanol (5 ml) the mixture was stirred overnight. The solvent was evaporated under reduced pressure and the residue was purified by column chromatography on silica gel using methylene chloride: methanol (100:5) as eluent. Treating the residue with HCl/diethyl ether and filtration gave 0.01 g (11%) of the title compound.

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.35 (s, 3H), 2.4 (s, 3H), 2.45 (s, 6H), 3.55 (s, 3H), 4.35 (d, 2H), 4.45 (s, 2H), 4.85 (bs, 1H), 6.2 (s, 1H), 7.05-7.15 (m, 3H), 7.3 (s, 1H)

25 *Example 1.69*

*Synthesis of N-(8-((2,6-dimethylbenzyl)amino)-2,3-dimethylimidazo[1,2-a]pyridin-7-yl)acetamide*

7-amino-2,3-dimethyl-8-(2,6-dimethylbenzylamino)-imidazo[1,2-a]pyridine (example 77) (0.16 g, 0.53 mmol) was dissolved in methylene chloride (5 ml) and acetic anhydride (60 mg) was added. The mixture was stirred over night at ambient temperature. A small amount of triethylamine was added and the solvent was removed under reduced pressure. Chromatography first with methylene chloride : methanol, 95:5 and secondly with methylene chloride:ethyl acetate, 50:50 gave after trituration with diethyl ether 87 mg (47 %) as white solid.

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.00 (s, 3H), 2.35 (s, 6H), 2.39 (s, 6H), 4.0 (bs 1H), 4.36 (d, 2H), 7.0-7.15 (m, 3H), 7.44 (d, 1H), 7.55 (d, 1H), 7.65 (bs, 1H)

*Example 1.70*

5 *Synthesis of N-(8-((2,6-dimethylbenzyl)amino)-2,3-dimethylimidazo[1,2-a]pyridin-7-yl)-N-methylsulfonylmethanesulfonamide*

7-amino-2,3-dimethyl-8-(2,6-dimethylbenzylamino)-imidazo[1,2-a]pyridine (example 77) (0.1 g, 0.34 mmol) was dissolved in methylene chloride (2 ml) followed by sodium  
10 carbonate (0.2 g, 1.9 mmol) and methanesulfonyl chloride (0.1 g, 0.87 mmol). The mixture was stirred at ambient temperature for 30 min. and after addition of 2 ml of water the mixture was stirred for 1 h. The organic layer was dried over sodium sulfate and the solvent evaporated *in vacuo*. Chromatography of the residue with methylene chloride: ethyl acetate 50:50, gave 4 mg (2.6 %) of the desired compound.

15

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.35 (s, 3H), 2.36 (s, 3H), 2.40 (s, 6H), 3.34 (s, 6H), 4.7 (t, 1H), 5.09 (d, 2H), 6.54 (d, 1H), 7.05-7.15 (m, 3H), 7.24 (d, 1H)

*Example 1.71*

20 *Synthesis of N-(8-((2,6-dimethylbenzyl)amino)-2,3-dimethylimidazo[1,2-a]pyridin-7-yl)(trifluoro)methanesulfonamide*

A mixture of 7-amino-2,3-dimethyl-8-(2,6-dimethylbenzylamino)-imidazo[1,2-a]pyridine (example 77) (0.1 g, 0.34 mmol), N-phenyl-bis(trifluoromethanesulfonyl)-amide (125  
25 mg, 0.35 mmol) and 3 ml of acetonitrile was refluxed for 20 h. The solvent was evaporated *in vacuo* and the residue was chromatographed with methylene chloride:methanol, 97:3 as the eluent. The isolated product was treated with ethyl acetate and diethyl ether and 23 mg (16 %) was obtained.

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.16 (s, 6H), 2.22 (s, 3H), 2.23 (s, 3H), 3.85 (bs, 2H), 4.12 (s, 2H), 6.70 (d, 1H), 6.85-7.0 (m, 3H), 7.56 (d, 1H)

*Example 1.72*

5 *Synthesis of 8-(2,6-dimethyl-4-fluorobenzyloxy)-3-chloro-2-methylimidazo[1,2-a]pyridine*

To a solution of 8-(2,6-dimethyl-4-fluorobenzyloxy)-2-methylimidazo[1,2-a]pyridine (0.6 g, 2.1 mmol) in acetic acid (13 ml) was added dropwise 1.1 M Cl<sub>2</sub> in acetic acid (2.2 ml, 2.43 mmol). The reaction mixture was stirred for 2 h. at room temperature and the solvent  
10 was evaporated under reduced pressure. The residue was solved in methylene chloride and was washed with water. The organic layer was separated, dried and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel using methylene chloride: ethyl acetate (100:4) as eluent. Treating the residue with diethyl ether and filtration gave 0.3 g (45 %) of the title compound.

15

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.4 (s, 6H), 2.45 (s, 3H), 5.2 (s, 2H), 6.65 (d, 1H), 6.75 (d, 2H), 6.8 (t, 1H), 7.7 (d, 1H)

*Example 1.73*

20 *Synthesis of 8-(2-(2,6-dimethylphenyl)ethenyl)-2,3-dimethylimidazo[1,2-a]pyridine*

To an icecooled suspension of sodium hydride (0.2 g, 5 mmol) (50 % in oil) in 1,2-dimethoxyethane (2 ml) was added diethyl (2,3-dimethylimidazo[1,2-a]pyridin-8-yl) methyl phosphonate and 2,6-dimethylbenzaldehyd. The reaction mixture was stirred in a  
25 nitrogen atmosphere for 1 h. at 0 °C and for 80 min at room temperature. The solvent was decanted and evaporated under reduced pressure. The residue was solved in methylene chloride and was washed with saturated sodium bicarbonate. The organic layer was separated, dried and evaporated under reduced pressure. Purification of the residue by column chromatography on silica gel using petroleum ether:ethyl acetate (30:8) as eluent  
30 gave 0.4 g (69 %) of the title compound.

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.45 (s, 9H), 2.5 (s, 3H), 6.85 (t, 1H), 7.05 (s, 3H), 7.1 (d, 1H), 7.25 (d, 1H), 7.75 (d, 1H), 7.95 (d, 1H)

*Example 1.74*

5 *Synthesis of 8-(2,6-dimethylphenetyl)-2,3-dimethylimidazo[1,2-a]pyridine*

8-(2-(2,6-dimethylphenyl)ethenyl)-2,3-dimethylimidazo[1,2-a]pyridine was solved in methanol (3 ml) and ethanol (2 ml) and Pd/C (10%) (40 mg) was added. The mixture was hydrogenated at room temperature and atmospheric pressure until the uptake of hydrogen  
10 ceased. Following filtration through celite, the solvents were evaporated under reduced pressure to give the title compound, (0.069 g, 100 %).

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.35 (s, 6H), 2.4 (s, 3H), 2.45 (s, 3H), 3.05-3.2 (m, 4H), 6.7 (t, 1H), 6.85 (d, 1H), 7.0 (s, 3H), 7.7 (d, 1H)

15

*Example 1.75*

*Synthesis of N-((2,3-dimethylimidazo[1,2-a]pyridin-8-yl)methyl)-2,6-dimethylaniline hydrochloride*

20 8-chloromethyl-2,3-dimethylimidazo[1,2-a]pyridine (0.06 g, 0.31 mmol), 2,6-dimethylaniline (0.039 g, 0.32 mmol), sodium carbonate (0.15 g, 1.4 mmol) and sodium iodide (0.06 g, 0.4 mmol) in acetone (3 ml) was stirred for 20 h. at room temperature. Methylene chloride was added and the solids were isolated by filtration and the solvents were evaporated under reduced pressure. The residue was purified by column  
25 chromatography on silica gel using methylene chloride:methanol (2:1). The oily product was solved in methylene chloride and treated with HCl/diethyl ether to give the title compound, 0.02 g. (18%)

30 <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.25 (s, 6H), 2.4 (s, 3H), 2.45 (s, 3H), 4.5 (s, 2H), 6.7 (t, 1H), 6.8 (t, 1H), 6.95 (d, 2H), 7.05 (d, 1H), 7.75 (d, 1H) (base)



*Example 1.76**Synthesis of 8-((2,6-dimethylphenoxy)methyl)-2,3-dimethylimidazo[1,2-a]pyridine.*

5 To a suspension of potassium hydroxide (0.035 g, 0.62 mmol), 2,6-dimethylphenol (0.075 g, 0.62 mmol) and 18-crown-6 (0.035 g) in 1,2-dimethoxyethane was added 8-chloromethyl-2,3-dimethylimidazo[1,2-a]pyridine (0.1 g, 0.51 mmol) in 1,2-dimethoxyethane (3 ml). The reaction mixture was stirred for 1.5 h. at room temperature and sodium iodide (0.035 g, 0.23 mmol) was added. The mixture was stirred for 3.5 h. and  
10 N,N-dimethylformamide (1 ml) and methanol were added and the solids were isolated by filtration. The filtrate was evaporated under reduced pressure, the residue was solved in methylene chloride and washed with saturated sodium bicarbonate. The organic layer was separated, dried and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel using methylene chloride:methanol (100:3.5) as  
15 eluent to give 0.11 (78%) of the title compound.

<sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): δ 2.3 (s, 6H), 2.4 (s, 3H), 2.45 (s, 3H), 5.3 (s, 2H), 6.9 (t, 1H), 6.95 (t, 1H), 7.05 (d, 2H), 7.55 (d, 1H), 7.75 (d, 1H)

20 *Example 1.77*

*Synthesis of 7-amino-2,3-dimethyl-8-(2,6-dimethylbenzylamino)-imidazo[1,2-a]pyridine*

A mixture of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-7-nitroimidazo[1,2-a]pyridine (45 mg, 0.139 mmol) Raney-Ni (0.1 g) and ethyl alcohol 4 ml was hydrogenated (H<sub>2</sub>, 1 bar) at  
25 40 °C for 3 h. The mixture was filtrated using a small amount of silica gel and the solvent was removed under reduced pressure. 40 mg (97 %) of the title compound was obtained.

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.30 (s, 3H), 2.34 (s, 3H), 2.49 (s, 6H), 3.85 (bs, 2H), 4.24 (s, 2H), 6.35 (d, 1H), 7.05-7.15 (m, 3H), 7.35 (d, 1H)

Example 1.78-1.79 were prepared according to Example 1.1

*Example 1.78*

*Synthesis of 8-(2-methoxycarbonylamino-6-methylbenzylamino)-2,3,6-trimethylmethyimidazo[1,2-a]pyridine*

Yield: 37 %

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.35 (s, 9H), 2.4 (s, 3H), 3.7 (s, 3H), 4.35 (d, 2H), 4.75 (bs, 1H), 6.2 (s, 1H), 6.95 (d, 1H), 7.1 (s, 1H), 7.2 (m, 1H), 7.5 (bs, 1H), 7.7 (bs, 1H)

*Example 1.79*

*Synthesis of 2,3-dimethyl-8-(4-trifluoromethoxybenzylamino)-imidazo[1,2-a]pyridine, hydrogen chloride*

Yield: 35 %

2.3 (s, 3H), 2.4 (s, 3H), 4.4 (d, 2H), 5.65 (t, 1H), 5.95 (d, 1H), 6.55 (t, 1H), 7.05-7.2 (m, 3H), 7.35 (d, 2H)

PREPARATION OF INTERMEDIATES

*Example 2.1*

*Synthesis of 2,6-dimethyl-4-fluorobenzylbromide*

A mixture of 3,5-dimethyl-fluorobenzene (5 g, 0.04 mol), paraformaldehyde (15 g), hydrobromic acid (70 ml) (30% in acetic acid) and acetic acid (25 ml) was stirred at ambient temperature for 4.5 h. To the mixture, water and petroleum ether were added and the organic layer was separated, dried over anhydrous sodium sulfate and evaporated.

carefully under reduced pressure. The residue was purified by column chromatography on silica gel with petroleum ether as eluent to give the desired product. (3.7 g, 43%).

$^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  2.5 (s, 6H), 4.55 (s, 2H), 6.75 (d, 2H)

5

#### *Example 2.2*

##### *Synthesis of 2-chloro-4,6-dimethylbenzylbromide.*

2-Chloro-3,5-dimethylbenzene (1.42 g, 0.01 mol) and paraformaldehyde (0.31 g, 0.01 mol)  
10 were added to 2 ml of hydrogenbromide (33%) in acetic acid. The mixture was stirred over night at +70°C. The reaction mixture was poured on 25 ml water and the product was extracted with diethyl ether. The organic layer was washed with water. The organic layer was dried ( $\text{Na}_2\text{SO}_4$ ) and evaporated. 1.1 g product (oil) was obtained. The  $^1\text{H-NMR}$   
15 spectrum shows that the substance was a mixture of the title compound and 4-chloro-2,6-dimethylbenzylbromide. The product was used as such without any further purification in the next synthetic step (Example 1.15).

$^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  2.28 (s, 6H), 4.51 (s, 2H), 7.04 (s, 2H).

20 Example 2.3-2.4 were prepared according to example 2.1

#### *Example 2.3*

##### *Synthesis of 2,4-dichloro-6-methylbenzylbromide*

25 Yield: 0.7 %

$^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  2.43 (s, 3H), 4.61 (s, 2H), 7.11 (d, 1H), 7.27 (d, 1H)

#### *Example 2.4*

30 *Synthesis of 4-fluoro-6-methyl-2-[2-(methylcarbonyloxy)ethyl]-benzylbromide*

Yield: 31 %

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.12 (s, 3H), 2.32 (s, 3H), 2.88 (t, 2H), 4.26 (t, 2H), 4.66 (s, 2H), 6.65-6.8 (m, 2H)

5

*Example 2.5*

*Synthesis of 8-amino-2,3,6-trimethylimidazo[1,2-a]pyridine*

To a solution of 2,3-diamino-5-methylpyridine (2.0 g, 16 mmol) in ethanol (100 ml) was added 3-bromo-2-butanone (2.4 g, 16 mmol). The reaction mixture was refluxed for 16 h. An additional amount of 3-bromo-2-butanone (1.0 g 6.7 mmol) and triethylamine (1.0 g, 9.9 mmol) were added and the mixture was refluxed for 2 h. The ethanol was evaporated under reduced pressure and the residue was treated with methylene chloride and a solution of bicarbonate. The organic layer was separated, dried over sodium sulfate and evaporated under reduced pressure. The oily residue was purified by column chromatography on silica gel, using methanol : methylene chloride (1: 20) as eluent to give the desired product (1.05 g, 37%).

<sup>1</sup>H-NMR (300 MHz, DMSO-d<sub>6</sub>): δ 2.15 (s, 3H), 2.25 (s, 3H), 2.3 (s, 3H), 5.45 (bs, 2H), 6.05 (s, 1H), 7.20 (s, 1H).

20

*Example 2.6*

*Synthesis of 8-amino-3-carboethoxy-2,6-dimethylimidazo[1,2-a]pyridine*

A stirred mixture of 2,3-diamino-5-methylpyridine (4.0 g, 32.5 mmol) and (5.9 g, 36.0 mmol) of ethyl - chloroacetoacetate in 75 ml abs. ethanol was refluxed over night. The ethanol was evaporated under reduced pressure. The residue was dissolved in 2 M HCl and washed 3 times with diethyl ether, pH was adjusted to 9 and extracted 3 times with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and evaporated. The residue was purified by column chromatography on silica gel with dichloromethane : methanol 95 : 5 as eluent to give the title product 2.0 g (28%).

30

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>) : δ 1.42 (t, 3H), 2.28 (s, 3H), 2.65 (s, 3H), 4.40 (q, 2H), 4.47 (s, 2H), 6.40 (s, 1H), 8.55 (s, 1H).

5 *Example 2.7*

*Synthesis of 3-carboethoxy-2,6-dimethyl-8-(2,6-dimethylbenzylamino) imidazo[1,2-a]pyridine*

A stirred mixture of 8-amino-2,6 dimethylimidazol [1,2-a]pyridine  
10 (1.2 g, 5.1 mmol), zinc(II)chloride (0.84 g, 6.2 mmol) and 2,6 - dimethylbenzaldehyde (0.84 g, 6.2 mmol) in 50 ml methanol was treated with sodium cyanoborohydride (0.39 g, 6.2 mmol) and was refluxed for 5 h. The methanol was evaporated under reduced pressure and the residue was dissolved in dichloromethane and 40 ml 2 M sodium hydroxide. The organic layer was separated, dried over sodium sulfate and evaporated under reduced  
15 pressure. The residue was purified by column chromatography on silica gel, eluent petroleum ether (40 - 60) : isopropyl ether 8:2, in yield of 0.8 g, (44%) of the title compound.

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 1.44 (t, 3H), 2.35 (d, 9H), 2.60 (s, 3H), 4.33 (d, 2H), 4.40  
20 (q, 2H), 4.6 (s, 1H), 6.60 (s, 1H), 7.10 (d, 2H), 7.25 (m, 1H), 8.50 (s, 1H).

*Example 2.8*

*Synthesis of 3-carboethoxy-2,6-dimethyl-8-(2,6-dimethyl-4-fluorobenzylamino)-imidazo[1,2-a]pyridine*

25

A stirred mixture of (1.1 g, 4.7 mmol) 8-amino-3-carboethoxy-2,6-dimethylimidazo[1,2-a]pyridine (1.2g, 5.7 mmol) 2,6-dimethyl-4-fluorobenzylbromide, (1.0 g, 7.5 mmol) potassium carbonate and (0.1 g) sodium iodide in 15 ml acetonitrile was refluxed over night. After evaporation of the solvent under reduced pressure the residue was dissolved in  
30 dichloromethane and washed with water, the organic layer was separated dried over sodium sulfate and evaporated under reduced pressure. The residue was purified by column

chromatography on silica gel, eluent petroleum ether (40-60) : isopropyl ether 7:3 to give 0.8 g, (47%) of the title compound.

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 1.42 (t, 3H), 2.36 (s, 9H), 2.62 (2, 3H), 4.45 (d, 2H), 4.48 (q, 2H), 4.54 (s, 1H), 6.30, (s, 1H), 6.75 (d, 2H), 8.55 (s, 1H).

#### Example 2.9

*Synthesis of 2,6-dimethyl-8-(2,6-dimethyl-4-fluorobenzylamino) imidazo[1,2- a]pyridine-3-carboxylic acid*

10

A mixture of 3-carboethoxy-2,6-dimethyl-8-(2,6-dimethylbenzylamino) imidazo[1,2-a]pyridine (0.4 g, 1.1 mmol), sodium hydroxide (2M, 6 ml) and dioxane (6 ml) was refluxed for 20 min. The dioxane was removed under reduced pressure. pH was adjusted to pH=7 with 2M HCl and the formed precipitate was filtered off . 0.23 g (75 %) of the title compound was obtained.

15

Example 2.10 was prepared according to example 2.9.

#### Example 2.10

20

*Synthesis of 2,6-dimethyl-8-(2,6-dimethylbenzylamino) imidazo[1,2- a]pyridine-3-carboxylic acid*

Yield:100 %

25

#### Example 2.11

*Synthesis of ethyl 8-amino-3-methylimidazo[1,2-a]pyridine-2-carboxylate*

30

A solution of 2,3-diaminopyridine (6.8 g, 62 mmol) and 3-bromo-2-oxo-butyric acid ethyl ester (13 g, 62 mmol) in 1,2-dimethoxyethane (150 ml) was refluxed for 2 h. Sodium carbonate (6.5 g, 62 mmol) was added and the mixture was refluxed for 2 h. The solids were isolated by filtration and washed with dichloromethane:methanol (10:1). The filtrate and washings were combined the solvents were removed under reduced pressure. The oily

residue was washed with petroleum ether and was purified twice by column chromatography on silica gel using 1) dichloromethane:methanol (10:1) 2) ethyl acetate as eluent to give 4.6 g (34%) of the title compound.

5  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  1.45 (t, 3H), 2.75 (s, H), 4.5 (q, 2H), 4.65 (bs, 2H), 6.35 (d, 1H), 6.7 (t, 1H), 7.35 (d, 1H)

#### *Example 2.12*

*Synthesis of ethyl 8-(2,6-dimethylbenzylamino)-3-methylimidazo[1,2-a]pyridine-2-*  
10 *carboxylate*

Ethyl 8-amino-3-methylimidazo[1,2-a]pyridine-2-carboxylate (4.6 g, 21 mmol), 2,6-dimethylbenzyl chloride (3.2 g, 21 mmol), sodium carbonate (4.4 g, 42 mmol) and a cat. amount of potassium iodide were added to acetonitrile (50 ml) and refluxed for 3 h. ,  
15 stirred for 20 h. at room temperature and refluxed for 1 h. The solids were removed by filtration and the solvents were evaporated under reduced pressure. The residue was dissolved in methylene chloride and washed with water. The organic layer was separated, dried ( $\text{Na}_2\text{SO}_4$ ) and evaporated under reduced pressure. Purification of the residue by column chromatography on silica gel using methylene chloride:methanol (10:1) as eluent  
20 and crystallization from ethyl acetate gave 4.0 g (56%) of the desired product.

$^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  1.4 (t, 3H), 2.4 (s, 6H), 2.75 (s, 3H), 4.35 (d, 2H), 4.45 (q, 2H), 5.15 (t, 1H), 6.25 (d, 1H), 6.85 (t, 1H), 7.05-7.2 (m, 3H), 7.35 (d, 1H)

#### *Example 2.13*

*Synthesis of 8-(2,6-dimethylbenzylamino)-2-hydroxymethyl-3-methylimidazo[1,2-*  
25 *a]pyridine*

Ethyl 8-(2,6-dimethylbenzylamino)-3-methylimidazo[1,2-a]pyridine-2-carboxylate (5.2 g, 0.015 mol) was solved in tetrahydrofuran (100 ml) and  $\text{LiAlH}_4$  (1.15 g 0.03 mol) was  
30 added. After stirring the mixture at room temperature. for 45 min, 1.15 ml of water was added dropwise, followed by 1.15 ml of 15% sodium hydroxide and then 3.45 ml of water. The solids were removed by filtration and washed thoroughly with methylene chloride. The filtrate and washings were combined and dried and the solvents were removed under  
35 reduced pressure. Purification of the residue by column chromatography on silica gel using methylene chloride : methanol (10:2) as eluent gave 3.2 g (73%) of the title compound.

<sup>1</sup>H-NMR (300 MHz, DMSO-d<sub>6</sub>): δ 2.35 (s, 6H), 2.4 (s, 3H), 4.35 (d, 2H), 4.5 (d, 2H), 4.85 (t, 1H), 4.9 (t, 1H), 6.3 (s, 1H), 6.8 (t, 1H), 7.05-7.2 (m, 3H), 7.55 (d, 1H)

5 *Example 2.14*

*Synthesis of 8-(2,6-dimethylbenzylamino)-2-chloromethyl-3-methylimidazo[1,2-a]pyridine*

To a solution of 8-(2,6-dimethylbenzylamino)-2-hydroxymethyl-3-methylimidazo[1,2-a]pyridine (1.0 g, 3.4 mmol) in methylene chloride (50 ml) was added dropwise thionyl chloride (0.5 g, 3.4 mmol) solved in methylene chloride (10 ml) at 5 °C. The reaction  
10 mixture was stirred 2 h. at 5 °C. To the mixture was washed with a saturated bicarbonate solution, the organic layer was separated, dried (Na<sub>2</sub>SO<sub>4</sub>) and evaporated under reduced pressure to give 1.0 g (93%) of the title compound.

15 <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.4 (s, 6H), 2.5 (s, 3H), 4.35 (d, 2H), 4.75 (s, 2H), 4.9 (bs, 1H), 6.25 (d, 1H), 6.8 (t, 1H), 7.05-7.15 (m, 3H), 7.25 (d, 1H)

*Example 2.15*

*Synthesis of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)imidazo[1,2-a]pyridine*

20

A mixture of 8-amino-2,3-dimethylimidazo[1,2-a]pyridine (0.7 g, 4.34 mmol), sodium carbonate (2.0 g), sodium iodide (0.3 g), 2,6-dimethylbenzylchloride (0.671 g, 4.34 mmol) and acetone (30 ml) was stirred overnight. The reaction mixture was filtered and the solvent was removed in vacuo. The residue was dissolved in methylene chloride and  
25 washed with aqueous NaHCO<sub>3</sub>. The organic layer was separated and the solvent was evaporated. The crude product was purified by flash chromatography eluting with CH<sub>2</sub>Cl<sub>2</sub>/MeOH to give 0.7 g of the title compound.

30 <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 7.25 (d, J=7.7 Hz, 1H), 7.14-7.09 (m, 1H), 7.03 (d, J=7.7 Hz, 2H), 6.73 (t, J=7.7 Hz, 1H), 6.21 (d, J=7.7 Hz, 1H), 4.79 (br "t", 1H), 4.34 (d, J=4.5 Hz, 2H), 2.38 (s, 6H), 2.34 (s, 6H).

*Example 2.16*



*Synthesis of 8-amino-3-acetyl-2-methylimidazo[1,2-a]pyridine*

A mixture of 2,3-diaminopyridine (7 g, 64.1 mmol), 3-chloroacetylacetone (8.6 g, 64.1 mmol) in ethyl alcohol (80 ml) was refluxed for 9 hours. The solvent was removed under reduced pressure and the residue dissolved in methylene chloride. A sodium bicarbonate solution was added and the organic layer was separated. The aqueous layer was extracted twice with methylene chloride. The combined organic layer was dried and evaporated under reduced pressure. Chromatography of the residue on silica gel (methylene chloride:methanol, 100:5) gave a product which after recrystallisation from ethyl acetate gave 1.9 g (15 %) of the title compound.

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.6 (s, 3H), 2.75 (s, 3H), 4.5 (bs, 2H), 6.6 (d, 1H), 6.8 (t, 1H), 9.15 (t, 1H)

Example 2.17 was prepared according to example 1.1

*Example 2.17**Synthesis of 3-acetyl-8-(2,6-dimethylbenzylamino)-2-methylimidazo[1,2-a]pyridine*

Yield: 72 %

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.4 (s, 6H), 2.6 (s, 3H), 2.7 (s, 3H), 4.35 (d, 2H), 4.85 (bs, 1H), 6.55 (d, 1H), 7.9 (t, 1H), 7.0-7.2 (m, 3H), 9.1 (d, 1H)

*Example 2.18*

Synthesis of 1-[8-(2,3-dimethylbenzylamino)-2-methylimidazo[1,2-a]pyridine-3-yl]-1-ethanol

To a mixture of 3-acetyl-8-(2,6-dimethylbenzylamino)-2-methylimidazo[1,2-a]pyridine (500 mg, 1.63 mmol) and methanol (20 ml) was sodium borohydride (62 mg, 1.63 mmol) added in portions. Tetrahydrofuran was added and the mixture stirred for 1 hour. TLC showed starting material and sodium borohydride (62 mg, 1.63 mmol) was added and the mixture stirred for 1.5 hour. The solvent was removed under reduced pressure and to the

residue, methylene chloride and water was added. pH was adjusted to pH=3 with hydrogen chloride (conc.) and thereafter alkaline with sodium bicarbonate. The methylene chloride layer was separated washed with water, dried over sodium sulfate and evaporated *in vacuo*. The residue was treated with ethanol/ ethyl acetate and after filtration (410 mg, 81 %).

5

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 1.6 (d, 3H), 2.15 (s, 3H), 2.4 (s, 3H), 4.35 (d, 2H), 4.8 (bs, 1H), 5.2 (q, 1H), 6.25 (d, 1H), 6.7 (t, 1H), 7.0-7.2 (m, 3H), 6.8 (d, 1H)

*Example 2.19 and 2.20*

10 *Synthesis of 2-chloro-6-methylbenzylbromide and 3 chloro-2-methylbenzylbromide*

A mixture of 3-chloro-o-xylene (20g, 142.2 mmol), N-bromo succinimid (26.57 g, 149.3 mmol), dibenzoylperoxid (0.67 g) and tetrachloromethane (200 ml) was refluxed for 5 hours. After filtration the filtrate was washed with sodium hydrogensulfite and water. The  
15 organic layer was dried over sodium sulfate and evaporated *in vacuo*. Chromatography (SiO<sub>2</sub>) (petroleum ether: ethyl acetate, 100:4) gave a 10 g fraction containing a mixture of the two title compounds 2-chloro-6-methylbenzylbromide (2.19): 3-chloro-2-methylbenzylbromide (2.20), 1:0.7. This mixture was used without further purification.

20 Example 2.21 was prepared according to example 2.8

*Example 2.21*

*Synthesis of ethyl 8-(2,6-dimethylbenzylamino)-2-methylimidazo[1,2-a]pyridine-3-carboxylate*

25

Yield: 34%

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 1.4 (t, 3H), 2.35 (s, 3H), 2.45 (s, 3H), 2.6 (s, 3H), 4.4 (q, 2H), 4.5 (d, 2H), 4.9 (bs, 1H), 6.35 (s, 1H), 7.05- 7.35 (m, 3H), 8.5 (s, 1H)

30

Example 2.22, 2.23 (mixture), 2.24, 2.25 and 2.26 were prepared according to example 2.19 and 2.20.

*Example 2.22 and 2.23*

*Synthesis of 2-bromo-6-methylbenzylbromide (2.22) and 3-bromo-2-methylbenzylbromide (2.23)*

Yield: 78 % (16.8 g of a fraction containing a mixture of the two title compounds  
5 (2.22:2.23), 1:0.7)

*Example 2.24*

*Synthesis of ethyl 2-bromomethyl-3-methylbenzoate*

10 Yield: 26 %

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 1.4 (t, 3H), 2.45 (s, 3H), 4.4 (q, 2H), 5.0 (s, 2H), 7.2-7.4 (m, 2H) 7.75 (d, 1H)

15 *Example 2.25 and 2.26*

*Synthesis of 2-bromomethyl-3-methylbenzonitrile (2.25) and 3-bromomethyl-2-methylbenzonitrile (2.26)*

Yield: 5.6 % (2.25)  
20 18 % (7.6g of fraction containing a mixture of the two compounds (2.25:2.26), 1.8:1)

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) *Example 2.25*: δ 2.45 (s, 3H), 4.70 (s, 2H), 7.2-7.6 (m, 3H)

25 *Example 2.27*

*Synthesis of 2-(2,3-dimethylimidazo[1,2-a]pyridin-8-yl)-4-methyl-1-isoindoline*

The title compound was obtained in the synthesis of example 1.15 (8-(2-ethoxycarbonyl-6-methylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridine).

30

Yield: 24 %

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.91 (s, 3H), 2.92 (s, 3H), 2.94 (s, 3H), 5.4 (s, 2H), 6.9 (t, 1H), 7.35-7.45 (m, 2H), 7.65 (d, 1H), 7.7-7.85 (m, 2H)

35

*Example 2.28**Synthesis of 2-(((2,3-dimethylimidazo[1,2-a]pyridin-8-yl)amino)methyl)-3-methylbenzoic acid*

5 A mixture of Example 2.27 (700 mg, 2.4 mmol), sodiumhydroxide (15 ml, 10M) and ethyl alcohol (30 ml) and water (7.5 ml) was refluxed for 4 days. The organic solvent was evaporated *in vacuo*. The residue was partitioned between methylene chloride and water. The aqueous layer was cooled and hydrogen chloride (conc.) was added. After extraction with methylene chloride, a mixture of the title compound and Example 2.27 (150 mg) was  
10 obtained. The product crystallize from ethyl alcohol and after filtration the precipitate was washed with ethyl alcohol and methylene chloride. 60 mg (8 %) of the title compound was obtained.

<sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD): δ 2.35 (s, 3H), 2.45 (s, 3H), 2.47 (s, 3H), 4.65 (s, 2H), 6.95  
15 (d, 1H), 7.2-7.45 (m, 3H), 7.6 (d, 1H), 7.8 (d, 1H)

*Example 2.29**Synthesis of 2-bromo-1-methoxymethyl-3-methylbenzene*

20 To a stirred solution of 2-bromo-3-methylbenzylbromide (5.2 g, 0.0197 mol) in methanol (30 ml) was added saturated sodiumbicarbonate (5 ml) and the mixture was refluxed overnight. The mixture was neutralised with acetic acid and the solvent was evaporated under reduced pressure. Chromatography of the residue on silica gel using hexane: methylene chloride (7/3) as eluent gave 4.2 g (99 %) of the title compound.

25

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.43 (s, 3H), 3.47 (s, 3H), 4.55 (s, 2H), 7.18-7.30 (m, 3H)

Example 2.30 was prepared according to Example 2.29

30 *Example 2.30*

*Synthesis of 2-bromo-1,3-bis(methoxymethyl)benzene*

Yield: 94 %

5  $^1\text{H-NMR}$  (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  3.5 (s, 6H), 4.6 (2, 4H), 7.35-7.45 (m, 3H)

*Example 2.31**Synthesis of 2-bromo-3-methylbenzylcyanid*

10 A mixture of 2-brom-3-methylbenzylbromide (25 g, 0.095 mol) and potassium cyanide (16 g, 0.25 mol) in dimethylformamide (100 ml) was stirred at 90 °C for 20 h. The solvent was evaporated under reduced pressure and to the residue were added toluene and water. The organic layer was separated washed with water, separated and evaporated under reduced pressure. Purification of the residue by column chromatography on silica gel using  
15 methylene chloride as eluent gave 8.8 g (44 %) of the title compound.

$^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  2.42 (s, 3H), 3.83 (s, 2H), 7.21-7.35 (m, 3H)

*Example 2.32*

20 *Synthesis of 2-bromo-3-methylphenyl acetic acid*

2-bromo-3-methylbenzylcyanid (8.8 g, 42 mmol) was added to a mixture of conc sulfuric acid (50 ml) and water (60 ml) and was refluxed overnight. Water (150 ml) and diethyl ether were added and the organic layer was separated. To the organic layer was added a  
25 saturated sodium bicarbonate solution and the aqueous layer was separated. The aqueous layer was made acidic by additon of conc sulfuric acid. The acidic water solution was extracted with diethyl ether and the organic layer was washed with water, dried ( $\text{Na}_2\text{SO}_4$ ) and evaporated under reduced pressure to give 6.5 g of the title compound.

30  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  2.43 (s, 3H), 3.87 (s, 3H), 7.1-7.2 (m, 3H)

*Example 2.33**Synthesis of ethyl 2-bromo-methylphenyl acetate*

To a stirred mixture of 2-bromo-3-methylphenyl acetic acid (4.8 g, 21 mmol) in ethanol  
5 (50 ml) was added a small amount of conc. sulfuric acid and the mixture was refluxed  
overnight. Sodium carbonate (1 g) was added and the solvent was evaporated under  
reduced pressure. To the residue were added methylene chloride and water. The organic  
layer was separated and evaporated under reduced pressure. Purification of the residue by  
column chromatography on silica gel using methylene chloride as eluent gave 2.0 g (37 %)  
10 of the desired product as an oil.

$^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  1.27 (t, 3H), 2.43 (s, 3H), 3.81 (s, 2H), 4.18 (q, 2H), 7.2-  
7.4 (m, 3H)

15 *Example 2.34*

*Synthesis of 2-(2-bromo-3-methylphenyl)ethanol*

To a stirred solution of 2-bromo-methylphenyl acetate (2 g, 7.9 mmol) in tetrahydrofuran  
(30 ml) was added  $\text{LiAlH}_4$  (0.8 g, 21 mmol) at 0-5 °C. After stirring the mixture at 0-5 °C  
20 for 2 h., 0.8 ml of water was added dropwise, followed by 0.8 ml of 15% sodium hydroxide  
and then 2.4 ml of water. The solids were removed by filtration and washed with  
tetrahydrofuran and tetrahydrofuran/methanol (9/1). The filtrate and washings were  
combined and the solvents were removed under reduced pressure. The residue was solved  
in methylene chloride/methanol (9/1) and was filtrated through silica gel (0.5 g). The  
25 solvent was evaporated under reduced pressure to give 1.6 g (95 %) of the title compound.

$^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  2.43 (s, 3H); 3.07 (t, 2H), 3.89 (t, 2H), 7.1-7.3 (m, 3H)

*Example 2.35*

30 *Synthesis of 2-(2-bromo-3-methylphenyl)ethyl methylether*

To a stirred solution of 2-(2-bromo-3-methylphenyl)ethanol ( 1.6 g, 7.4 mmol) in tetrahydrofuran (20 ml) was added sodium hydride (50 % in oil) (0.46 g, 9.6 mmol). After stirring the mixture for 15 min methyl iodide (1.6 g, 11.3 mmol) was added and the  
5 reaction mixture was stirred for 3 h. at room temperature. Water (0.2 g) was added and then acetic acid (0.2 g). The solvents were evaporated under reduced pressure and purification of the residue by column chromatography on silica gel using methylene chloride as eluent gave 1.5 g (89 %) of the desired product as an oil.

10 <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.42 (s, 3H), 3.07 (t, 2H), 3.38 (s, 3H), 3.62 (t, 2H), 7.1-7.25 (m, 3H)

#### Example 2.36

##### *Synthesis of 2-(2-methoxyethyl)-6-methylbenzaldehyd*

15

To a stirred solution of 2-(2-bromo-3-methylphenyl)ethyl methylether (1.5 g, 6.5 mmol) in anhydrous tetrahydrofuran (10 ml) was added magnesium (turnings) (0.16 g, 6.6 mmol). The mixture was refluxed in a nitrogen atmosphere until the reaction started and then stirred without heating for 15 min. The mixture was stirred at 50 °C overnight. The mixture  
20 was cooled to room temperature and N,N-dimethylformamide (0.7 g) was added and the mixture was stirred for 30 min. A saturated ammonium chloride solution (10 ml) was added and the mixture was stirred for 1 h. at room temperature. Toluene (20 ml) was added and the organic layer was separated, dried (Na<sub>2</sub>SO<sub>4</sub>) and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel using  
25 methylene chloride as eluent to separate the lipophilic biproducts and methylene chloride/diethyl ether(7:3) as eluent to isolate (0.17 g, (15 %) of the title compound as an oil.

30 <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.61 (s, 3H), 3.25 (t, 2H), 3.36 (s, 3H), 3.61 (t, 2H), 7.1-7.4 (m, 3H)

Example 2.37, 2.38 and 2.39 were prepared according to Example 2.36

*Example 2.37*

5 *Synthesis of 2-methoxymethyl-6-methylbenzaldehyd*

Yield: 90 %

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.64 (s, 3H), 3.43 (s, 3H), 4.78 (s, 2H), 7.2-7.45 (m, 3H),  
10 10.55 (s, 1H)

*Example 2.38*

*Synthesis of 2,6-bis(methoxymethyl)-benzaldehyd*

15 Yield: 79 %

<sup>1</sup>H-NMR (500 MHz, CDCl<sub>3</sub>): δ 3.5 (s, 6H), 4.85 (s, 4H), 7.6 (s, 3H), 10.55 (s, 1H)

*Example 2.39*

20 *Synthesis of 2,5-dimethylthiophene-3-carbaldehyde*

Yield: 57 %

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.41 (s, 3H), 2.74 (s, 3H), 6.62 (s, 1H), 10.11 (s, 1H)

25

BIOLOGICAL TESTS

*1. In vitro experiments*

30 *Acid secretion inhibition in isolated rabbit gastric glands*

Inhibiting effect on acid secretion *in vitro* in isolated rabbit gastric glands was measured as described by Berglindh et al. (1976) Acta Physiol. Scand. 97, 401-414.

35 *Determination of H<sup>+</sup>.K<sup>+</sup>-ATPase activity*



Membrane vesicles (2.5 to 5 µg) were incubated for 15 min at +37°C in 18 mM Pipes/Tris buffer pH 7.4 containing 2 mM MgCl<sub>2</sub>, 10 mM KCl and 2 mM ATP. The ATPase activity was estimated as release of inorganic phosphate from ATP, as described by LeBel et al.

5 (1978) Anal. Biochem. 85, 86-89.

## *2. In vivo experiments*

### *Inhibiting effect on acid secretion in female rats*

10

Female rats of the Sprague-Dawley strain are used. They are equipped with cannulated fistulae in the stomach (lumen) and the upper part of the duodenum, for collection of gastric secretions and administration of test substances, respectively. A recovery period of 14 days after surgery is allowed before testing commenced.

15

Before secretory tests, the animals are deprived of food but not water for 20 h. The stomach is repeatedly washed through the gastric cannula with tap water (+37°C), and 6 ml Ringer-Glucose given subcutaneously. Acid secretion is stimulated with infusion during 2.5-4 h (1.2 ml/h, subcutaneously) of pentagastrin and carbachol (20 and 110 nmol/kg·h, respectively), during which time gastric secretions are collected in 30-min fractions. Test substances or vehicle are given either at 60 min after starting the stimulation (intravenous and intraduodenal dosing, 1 ml/kg), or 2 h before starting the stimulation (oral dosing, 5 ml/kg, gastric cannula closed). The time interval between dosing and stimulation may be increased in order to study the duration of action. Gastric juice samples are titrated to pH 7.0 with NaOH, 0.1 M, and acid output calculated as the product of titrant volume and concentration.

20

25

Further calculations are based on group mean responses from 4-6 rats. In the case of administration during stimulation; the acid output during the periods after administration of test substance or vehicle are expressed as fractional responses, setting the acid output in the 30-min period preceding administration to 1.0. Percentage inhibition is calculated from the

30

fractional responses elicited by test compound and vehicle. In the case of administration before stimulation; percentage inhibition is calculated directly from acid output recorded after test compound and vehicle.

5     *Bioavailability in rat*

Adult rats of the Sprague-Dawley strain are used. One to three days prior to the experiments all rats are prepared by cannulation of the left carotid artery under anaesthesia. The rats used for intravenous experiments are also cannulated in the jugular vein (Popovic  
10     (1960) J. Appl. Physiol. 15, 727-728). The cannulas are exteriorized at the nape of the neck.

Blood samples (0.1 - 0.4 g) are drawn repeatedly from the carotid artery at intervals up to 5.5 hours after given dose. The samples are frozen until analysis of the test compound.

15

Bioavailability is assessed by calculating the quotient between the area under blood/plasma concentration (AUC) curve following (i) intraduodenal (i.d.) or oral (p.o.) administration and (ii) intravenous (i.v.) administration from the rat or the dog, respectively.

20     The area under the blood concentration vs. time curve, AUC, is determined by the log/linear trapezoidal rule and extrapolated to infinity by dividing the last determined blood concentration by the elimination rate constant in the terminal phase. The systemic bioavailability (F%) following intraduodenal or oral administration is calculated as  
$$F(\%) = (AUC \text{ (p.o. or i.d.)} / AUC \text{ (i.v.)}) \times 100.$$

25

*Inhibition of gastric acid secretion and bioavailability in the conscious dog.*

Labrador retriever or Harrier dogs of either sex are used. They are equipped with a duodenal fistula for the administration of test compounds or vehicle and a cannulated  
30     gastric fistula or a Heidenhaim-pouch for the collection of gastric secretion.

Before secretory tests the animals are fasted for about 18 h but water is freely allowed. Gastric acid secretion is stimulated for up to 6.5 h infusion of histamine dihydrochloride (12 ml/h) at a dose producing about 80% of the individual maximal secretory response, and gastric juice collected in consecutive 30-min fractions. Test substance or vehicle is given orally, i.d. or i.v., 1 or 1.5 h after starting the histamine infusion, in a volume of 0.5 ml/kg body weight. In the case of oral administration, it should be pointed out that the test compound is administered to the acid secreting main stomach of the Heidenham-pouch dog.


10 The acidity of the gastric juice samples are determined by titration to pH 7.0, and the acid output calculated. The acid output in the collection periods after administration of test substance or vehicle are expressed as fractional responses, setting the acid output in the fraction preceding administration to 1.0. Percentage inhibition is calculated from fractional responses elicited by test compound and vehicle.

15

Blood samples for the analysis of test compound concentration in plasma are taken at intervals up to 4 h after dosing. Plasma is separated and frozen within 30 min after collection and later analyzed. The systemic bioavailability (F%) after oral or i.d. administration is calculated as described above in the rat model.

## CLAIMS

1. A compound of the formula I



or a pharmaceutically acceptable salt thereof, wherein

R<sup>1</sup> is

- 10 (a) H,
- (b) C<sub>1</sub>-C<sub>6</sub> alkyl,
- (c) C<sub>1</sub>-C<sub>6</sub> alkenyl,
- (d) CH<sub>2</sub>OH,
- (e) halogen, or
- 15 (f) thiocyano

R<sup>2</sup> is

- (a) C<sub>1</sub>-C<sub>6</sub> alkyl,
- (b) hydroxyalkyl ,
- 20 (c) C<sub>1</sub>-C<sub>6</sub> alkoxy C<sub>1</sub>-C<sub>6</sub> alkyl,
- (d) hydroxy C<sub>1</sub>-C<sub>6</sub> alkoxy C<sub>1</sub>-C<sub>6</sub> alkyl,
- (e) C<sub>1</sub>-C<sub>6</sub> alkylthio C<sub>1</sub>-C<sub>6</sub> alkyl,
- (f) cyano C<sub>1</sub>-C<sub>6</sub> alkyl or
- (g) halogenated C<sub>1</sub>-C<sub>6</sub> alkyl, or
- 25 (h) aminocarbonyl C<sub>1</sub>-C<sub>6</sub> alkyl,

R<sup>3</sup> is

- (a) H,
- (b) C<sub>1</sub>-C<sub>6</sub> alkoxy,
- (c) C<sub>1</sub>-C<sub>6</sub> alkyl,
- 5 (d) halogen,
- (e) hydroxy C<sub>1</sub>-C<sub>6</sub> alkyl,
- (f) hydroxy C<sub>1</sub>-C<sub>6</sub> alkoxy,
- (g) C<sub>1</sub>-C<sub>6</sub> alkoxy C<sub>1</sub>-C<sub>6</sub> alkyl,
- (h) C<sub>1</sub>-C<sub>6</sub> alkoxy C<sub>1</sub>-C<sub>6</sub> alkoxy,
- 10 (i) C<sub>1</sub>-C<sub>6</sub> alkoxycarbonyl,
- (j) C<sub>1</sub>-C<sub>6</sub> alkanoyl,
- (k) halogenated C<sub>1</sub>-C<sub>6</sub> alkyl,
- (l) NO<sub>2</sub>,
- (m) CN,
- 15 (n) C<sub>1</sub>-C<sub>6</sub> sulfonyl,
- (o) C<sub>1</sub>-C<sub>6</sub> sulfinyl,
- (p) C<sub>1</sub>-C<sub>6</sub> alkylthio,
- (q) C<sub>1</sub>-C<sub>6</sub> alkylaminosulfonyl,
- (r) C<sub>1</sub>-C<sub>6</sub> (alkyl)<sub>2</sub>aminosulfonyl,
- 20 (s) aminosulfonyl,
- (t) C<sub>1</sub>-C<sub>6</sub> alkylsulfonylamino,
- (u) C<sub>1</sub>-C<sub>6</sub> (alkylsulfonyl)<sub>2</sub>amino or
- (v) trifluoromethylsulfonylamino
- (x) C<sub>1</sub>-C<sub>6</sub> alkylcarbonylamino
- 25 (y) C<sub>1</sub>-C<sub>6</sub> alkoxycarbonylamino, or
- (z) C<sub>1</sub>-C<sub>6</sub> aminocarbonylamino, optionally substituted by one or two C<sub>1</sub>-C<sub>6</sub> alkyl groups,

R<sup>4</sup> is

- (a) H,
- 30 (b) C<sub>1</sub>-C<sub>6</sub> alkyl,

(c) halogenated C<sub>1</sub>-C<sub>6</sub> alkyl.


(d) C<sub>1</sub>-C<sub>6</sub> alkoxy, or

(e) halogen,

5

Ar is a with R<sup>5</sup>, R<sup>6</sup>, and/or R<sup>7</sup> substituted phenyl, thienyl, furanyl, naphthyl or pyridyl group.

X represents



R<sup>5</sup> is

(a) H,

(b) C<sub>1</sub>-C<sub>6</sub> alkyl,

15 (c) C<sub>1</sub>-C<sub>6</sub> alkoxy,

(d) hydroxy,

(e) hydroxy C<sub>1</sub>-C<sub>6</sub> alkyl,

(f) hydroxy C<sub>1</sub>-C<sub>6</sub> alkoxy,

(g) halogenated C<sub>1</sub>-C<sub>6</sub> alkyl,

20 (h) halogenated C<sub>1</sub>-C<sub>6</sub> alkoxy,

(i) C<sub>1</sub>-C<sub>6</sub> alkoxy C<sub>1</sub>-C<sub>6</sub> alkyl,

(j) halogen,

(k) hydroxy C<sub>1</sub>-C<sub>6</sub> alkoxy C<sub>1</sub>-C<sub>6</sub> alkyl,



(l) CN,

25 (m) C<sub>1</sub>-C<sub>6</sub> alkoxycarbonyl,

(n) C<sub>1</sub>-C<sub>6</sub> alkoxycarbonyloxy,

(o) C<sub>1</sub>-C<sub>6</sub> alkylsulfonyloxy.

(p) trifluoromethylsulfonyloxy,

- (q) C<sub>1</sub>-C<sub>6</sub> acyloxy C<sub>1</sub>-C<sub>6</sub> alkyl,  
 (r) C<sub>1</sub>-C<sub>6</sub> alkylsulfonyl C<sub>1</sub>-C<sub>6</sub> alkyl,  
 (s) C<sub>1</sub>-C<sub>6</sub> alkylsulfinyl C<sub>1</sub>-C<sub>6</sub> alkyl,  
 (t) C<sub>1</sub>-C<sub>6</sub> alkylthio C<sub>1</sub>-C<sub>6</sub> alkyl,  
 5 (u) C<sub>1</sub>-C<sub>6</sub> alkoxycarbonylamino C<sub>1</sub>-C<sub>6</sub> alkyl or  
 (v) aryl,  
 (x) amino C<sub>1</sub>-C<sub>6</sub> alkyl  
 (y) NHC=OR<sup>12</sup>  
 (z) H or C<sub>1</sub>-C<sub>4</sub> alkyl substituted  -group  
 10 (aa) H or C<sub>1</sub>-C<sub>4</sub> alkyl substituted  -group, or  
 (ab) C<sub>1</sub>-C<sub>6</sub> alkyl sulfonyl amino

R<sup>6</sup> is

- (a) H,  
 15 (b) C<sub>1</sub>-C<sub>6</sub> alkyl,  
 (c) halogen,  
 (d) hydroxy C<sub>1</sub>-C<sub>6</sub> alkyl,  
 (e) halogenated C<sub>1</sub>-C<sub>6</sub> alkyl,  
 (f) halogenated C<sub>1</sub>-C<sub>6</sub> alkoxy,  
 20 (e) C<sub>1</sub>-C<sub>6</sub> alkoxy C<sub>1</sub>-C<sub>6</sub> alkyl, or  
 (f) CN

R<sup>7</sup> is

- 25 (a) H,  
 (b) C<sub>1</sub>-C<sub>6</sub> alkyl,  
 (c) C<sub>1</sub>-C<sub>6</sub> alkoxy,  
 (d) halogen.

- (c) NO<sub>2</sub>,
- (f) halogenated C<sub>1</sub>-C<sub>6</sub> alkyl,
- (g) halogenated C<sub>1</sub>-C<sub>6</sub> alkoxy,
- (h) aryloxy, or
- 5 (i) CN

R<sup>8</sup> is

- (a) H or
- (b) C<sub>1</sub>-C<sub>6</sub> alkyl

10

R<sup>12</sup> is

- (a) C<sub>1</sub>-C<sub>6</sub> alkoxy,
- (b) C<sub>1</sub>-C<sub>6</sub> alkoxy C<sub>2</sub>-C<sub>4</sub> alkoxy,
- (c) NH<sub>2</sub>,
- 15 (d) hydroxy C<sub>2</sub>-C<sub>4</sub> alkoxy,
- (e) C<sub>1</sub>-C<sub>6</sub> alkyl carbonyloxy C<sub>2</sub>-C<sub>4</sub> alkoxy,
- (f) halogenated C<sub>2</sub>-C<sub>4</sub> alkoxy,
- (g) halogenated C<sub>1</sub>-C<sub>4</sub> alkyl,
- (h) hydroxy C<sub>1</sub>-C<sub>4</sub> alkyl,
- 20 (i) C<sub>1</sub>-C<sub>6</sub> alkyl carbonyloxy C<sub>1</sub>-C<sub>4</sub> alkyl,
- (j) aryl,
- (k) aryl C<sub>1</sub>-C<sub>4</sub> alkyl,
- (l) C<sub>1</sub>-C<sub>4</sub> sulfanyl C<sub>2</sub>-C<sub>4</sub> alkoxy,
- (m) C<sub>1</sub>-C<sub>4</sub> sulfinyl C<sub>2</sub>-C<sub>4</sub> alkoxy,
- 25 (n) C<sub>1</sub>-C<sub>4</sub> sulfonyl C<sub>2</sub>-C<sub>4</sub> alkoxy,

R<sup>5</sup> and R<sup>6</sup> are in the ortho positions relative to X

R<sup>7</sup> is in the meta or para position relative to X



$R^5$  and  $R^8$  may together form a hydroxy- or alkoxy- substituted 5- or 6- membered ring, provided that one of  $R^3$  and  $R^4 \neq H$  or halogen

provided also that at least one of  $R^5$ ,  $R^6$  and  $R^7 \neq H$

5 provided also that when  $R^5 = (y), (z), (aa)$  or  $(ab)$ , then one of  $R^3$  and  $R^4 \neq H$

provided also that when  $R^1 = H$ , then  $R^7 \neq CH_3$

provided also that when  $R^2 = CH_2OH$  or  $CH_2CN$ , then one of  $R^5$  and  $R^6 \neq H$

2. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein


10  $R^1$  is H,  $CH_3$ , or  $CH_2OH$ ,

$R^2$  is  $CH_3$ ,  $CH_2CH_3$ ,  $CH_2CH_2OH$ ,  $CH_2CH_2SCH_3$ ,  $CH_2CH_2OCH_3$ , or  $CH_2CH_2CN$ ;

$R^3$  is H,  $CH_3$ ,  $CH_2CH_3$ , F, Cl, Br,  $OCH_3$ ,  $OCH_2CH_3$ ,  $CH_2OH$ ,  $CH_2CH_2OH$ ,  $OCH_2CH_2OH$ ,  $CH_2CH_2OCH_3$ ,  $OCH_2CH_2OCH_3$ ,  $C=OOCH_3$ ,  $C=OOCH_2CH_3$ ,  $C=OCH_3$ ,  $C=OCH_2CH_3$ ,  $C=OCH(CH_3)_2$ , or  $C=OCH_2CH_2CH_3$ ,

15  $R^4$  is H,  $CH_3$ ,  $CH_2CH_3$ , F, Cl, Br,  $OCH_3$  or  $OCH_2CH_3$

Ar is phenyl, thienyl, furyl or naphthyl



$R^5$  is H,  $CH_3$ ,  $CH_2CH_3$ ,  $OCH_3$ , OH,  $CH_2OH$ ,  $CH_2OCH_3$ ,  $CH_2CH_2OH$ ,  $CH_2CH_2OCH_3$ ,  $OCH_2CH_2OH$ ,  $OC=OOCH_3$ ,  $OC=OCH_2CH_3$ ,  $OCHF_2$ ,  $OCF_3$ , F, Cl, Br, CN, phenyl,

20  $CH_2CH_2OC=OCH_3$ ,  $CH_2NHC=OOCH_3$  or  $CH_2NHC=OOCH_2CH_3$

$R^6$  is H,  $CH_3$ ,  $CH_2CH_3$ ,  $CF_3$ ,  $OCF_3$ ,  $OCF_2H$ , F, Cl, Br or  $CH_2OCH_3$

$R^7$  is H, F, Cl, Br,  $OCF_2H$ , or  $OCF_3$

$R^8$  is H,  $CH_3$ , or  $CH_2CH_3$ .

25 3. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein

$R^1$  is H,  $CH_3$  or  $CH_2OH$ ,


$R^2$  is  $CH_3$ ,  $CH_2CH_3$ ,  $CH_2OH$ ,  $CH_2SCH_3$ ,  $CH_2OCH_3$  or  $CH_2CN$

$R^3$  is H,  $CH_3$ ,  $CH_2CH_3$ ,  $OCH_3$ ,  $CH_2OH$ ,  $C=OOCH_3$ ,  $C=OOCH_2CH_3$ ,  $C=OCH_3$ ,  $C=OCH_2CH_3$ , or  $C=OCH_2CH_2CH_3$ .

$R^4$  is H, or  $CH_3$

Ar is phenyl, thienyl or furyl

5



$R^5$  is H,  $CH_3$ ,  $CH_2CH_3$ ,  $OCH_3$ , OH,  $CH_2OH$ ,  $CH_2OCH_3$ ,  $CH_2CH_2OH$ ,  $CH_2CH_2OCH_3$ ,  $OCH_2CH_2OH$ ,  $OC=OOCH_3$ ,  $OC=OCH_2CH_3$ ,  $OCHF_2$ ,  $OCF_3$ , F, Cl, Br, CN,  $CH_2CH_2OC=OCH_3$ ,  $CH_2NHC=OOCH_3$  or  $CH_2NHC=OOCH_2CH_3$

10  $R^6$  is H,  $CH_3$ ,  $CH_2CH_3$ ,  $CF_3$ ,  $OCF_3$ ,  $OCF_2H$ , F, Cl, Br or  $CH_2OCH_3$


$R^7$  is H, F, Cl Br,  $OCF_2H$ , or  $OCF_3$

$R^8$  is H or  $CH_3$


4. A process for the preparation of a compound according to any of claims 1 to 3

15 comprising;

reacting a compound of the general formula II



20 wherein  $X^1$  is  $NH_2$  or OH, and  $R^1$ ,  $R^2$ ,  $R^3$ , and  $R^4$  are as defined for Formula I, with a compound of the general Formula III




wherein "Ar" is as defined for Formula I and Y is a leaving group, such as a halide, tosyloxy or mesyloxy, in an inert solvent, such as acetone, acetonitrile, dimethoxyethane, methanol, ethanol or N,N-dimethylformamide, and optionally in the presence of a base, such as an alkali metal hydroxide, an alkali metal carbonate, or an organic amine, to give a compound of the general Formula I.

5. A process for the preparation of a compound according to any of claims 1 to 3 wherein X is NH comprising;


a) reacting a compound of the general formula IV

10




wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are as defined for Formula I, with a compound of the general Formula V

15



20

wherein Ar are as defined for Formula I, in an inert solvent in the presence of a Lewis acid, such as zinc chloride, under standard conditions to give a compound of the general formula VI




wherein  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$  and Ar are as defined for Formula I;


b) treating the compound of the general formula VI, wherein  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$  and Ar are as defined for Formula I, with sodium borohydride or sodium cyanoborohydride under standard condition in a solvent, such as methanol or ethanol, to give a compound of the general formula I, wherein X is NH.

6. A process for the preparation of a compound according to any of claims 1 to 3, wherein  $R^1$  is  $\text{CH}_2\text{OH}$  or H, comprising;


a) reacting a compound of the general formula VII



wherein  $X^1$  is  $\text{NH}_2$  or OH,  $R^2$ ,  $R^3$  and  $R^4$  are as defined for Formula I, with a compound of the general formula III



wherein Ar is as defined for Formula I and Y is a leaving group, such as a halide, tosyloxy or mesyloxy, to give a compound of the general Formula VIII




wherein  $R^2$ ,  $R^3$ ,  $R^4$ , Ar and X is as defined for Formula I, in an inert solvent, such as acetone, acetonitrile, dimethoxyethane, methanol, ethanol or N,N-dimethylformamide, and optionally in the presence of a base, such as an alkali metal hydroxide, an alkali metal carbonate, or an organic amine, under standard conditions,

b) treating a compound of the general formula VIII, wherein  $R^2$ ,  $R^3$ ,  $R^4$ , Ar and X is as defined for Formula I, with lithium aluminium hydride under standard conditions in an solvent, such as tetrahydrofuran or ether, to give a compound of the general Formula I, wherein  $R^1$  is  $\text{CH}_2\text{OH}$ , or


b) treating a compound of the general formula VIII, wherein  $R^2$ ,  $R^3$ ,  $R^4$ , Ar and X is as defined for Formula I, with aqueous base or acid, in an inert solvent, such as diphenylether, under standard conditions, to give a compound of the general formula I, wherein  $R^1$  is H.

7. A process for the preparation of a compound according to any of claims 1 to 3, wherein  $R^1$  is  $\text{CH}_2\text{OH}$  and X is NH, comprising;

a) reacting a compound of the general formula IX




with a compound of the general formula V



5

wherein Ar is as defined for Formula I, in an inert solvent under standard conditions, in the presence of a Lewis acid, such as zinc chloride to give a compound of the general formula the compounds of the Formula X




10

wherein R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and Ar are as defined for Formula I;

b) reacting a compound of the general formula X, wherein R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and Ar are as defined for Formula I with sodium borohydride or sodium cyanoborohydride under standard condition in an solvent, such as methanol or ethanol, to give a compound of the general formula XI

15



wherein  $R^2$ ,  $R^3$ ,  $R^4$  and Ar are as defined for Formula I;

5 c) reacting a compound of the general formula XI, wherein  $R^2$ ,  $R^3$ ,  $R^4$  and Ar are as defined for Formula I, with lithium aluminium hydride under standard conditions in an solvent, such as tetrahydrofuran or ether, to give a compound of the general Formula I, wherein  $R^1$  is  $\text{CH}_2\text{OH}$  and X is NH, or;


10 c) or treating a compound of the general formula XI, wherein  $R^2$ ,  $R^3$ ,  $R^4$ , and Ar is as defined for Formula I, with aqueous base or acid, in an inert solvent, such as diphenylether, under standard conditions, to give a compound of the general formula I, wherein  $R^1$  is H.

15


8. A process for the preparation of a compound according to any of claims 1 to 3, wherein X is  $\text{CH}_2\text{O}$ , comprising;

a) reacting a compound of the general formula XII

20



with an  $\alpha$ -halocarbonyl compound of the general formula  $R^2COCH(Z)R^1$  wherein  $R^1$  and  $R^2$  are as defined for Formula I and Z is a leaving group, such as Br or Cl, in an inert solvent, such as acetonitrile or ethanol, under standard conditions to give compounds of the general formula XIII



wherein  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ , and Ar is as defined for Formula I.

9. A pharmaceutical formulation containing a compound according to any one of claims 1 to 3 as active ingredient in combination with a pharmaceutically acceptable diluent or carrier.
10. Use of a compound according to any one of claims 1 to 3 for the manufacture of a medicament for the inhibition of gastric acid secretion.
11. Use of a compound according to any one of claims 1 to 3 for the manufacture of a medicament for the treatment of gastrointestinal inflammatory diseases.
12. Use of a compound according to any one of claims 1 to 3 the manufacture of a medicament for the treatment or prophylaxis of conditions involving infection by *Helicobacter pylori* of human gastric mucosa, wherein the said salt is adapted to be administered in combination with at least one antimicrobial agent.




13. A method for inhibiting gastric acid secretion which comprises administering to a mammal, including man, in need of such inhibition an effective amount of a compound according to any one of claims 1 to 3.
- 5 14. A method for the treatment of gastrointestinal inflammatory diseases which comprises administering to a mammal, including man, in need of such treatment an effective amount of a compound according to any one of claims 1 to 3.
- 10 15. A method for the treatment or prophylaxis of conditions involving infection by *Helicobacter pylori* of human gastric mucosa, which comprises administering to a mammal, including humans, in need of such treatment an effective amount of a compound as claimed in any one of claims 1 to 3, wherein the said salt is administered in combination with at least one antimicrobial agent.
- 15 16. A pharmaceutical formulation for use in the inhibition of gastric acid secretion wherein the active ingredient is a compound according to any one of claims 1 to 3.
17. A pharmaceutical formulation for use in the treatment of gastrointestinal inflammatory diseases wherein the active ingredient is a compound according to any one of claims 1 to 3.
- 20 18. A pharmaceutical formulation for use in the treatment or prophylaxis of conditions involving infection by *Helicobacter pylori* of human gastric mucosa, wherein the active ingredient is a compound according to any one of claims 1 to 3 in combination with at least one antimicrobial agent.
- 25

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification<sup>7</sup> : C07D 471/04, A61K 31/435</p>	<p>A3</p>	<p>(11) International Publication Number: <b>WO 00/11000</b> (43) International Publication Date: 2 March 2000 (02.03.00)</p>
<p>(21) International Application Number: PCT/SE99/01402 (22) International Filing Date: 18 August 1999 (18.08.99) (30) Priority Data: 9802794-9 21 August 1998 (21.08.98) SE (71) Applicant (for all designated States except US): ASTRA AKTIEBOLAG [SE/SE]; S-151 85 Södertälje (SE). (72) Inventors; and (75) Inventors/Applicants (for US only): AMIN, Kosrat [SE/SE]; Astra Hässle AB, S-431 83 Mölndal (SE). DAHLSTRÖM, Mikael [FI/SE]; Astra Hässle AB, S-431 83 Mölndal (SE). NORDBERG, Peter [SE/SE]; Astra Hässle AB, S-431 83 Mölndal (SE). STARKE, Ingemar [SE/SE]; Astra Hässle AB, S-431 83 Mölndal (SE). (74) Agent: ASTRA AKTIEBOLAG; Intellectual Property, Patents, S-151 85 Södertälje (SE).</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  Published With international search report. (88) Date of publication of the international search report: 15 June 2000 (15.06.00)</p>
<p>(54) Title: NEW COMPOUNDS</p> <div style="text-align: center;">  <p>(1)</p> </div> <p>(57) Abstract</p> <p>The present invention relates to novel compounds, and therapeutically acceptable salts thereof of formula (I), which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 99/01402

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>		
<b>IPC7: C07D 471/04, A61K 31/435</b> According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b>		
Minimum documentation searched (classification system followed by classification symbols)		
<b>IPC7: C07D</b>		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
<b>SE,DK,FI,NO classes as above</b>		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0033094 B1 (CHERING CORPORATION), 5 August 1981 (05.08.81)  --	1-11,16-17
X	US 5574042 A (TERUO OKU ET AL), 12 November 1996 (12.11.96)  --	1-11,16-17
X	WO 9424130 A1 (BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH), 27 October 1994 (27.10.94)  --	1-11,16-17
X	US 4450164 A (JAMES A. BRISTOL ET AL), 22 May 1984 (22.05.84)  --	1-11,16-17
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
9 February 2000		12 -02- 2000
Name and mailing address of the ISA: Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. +46 8 666 02 86		Authorized officer  Göran Karlsson/ELY Telephone No. +46 8 782 25 00

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/SE 99/01402

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9418199 A1 (BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH), 18 August 1994 (18.08.94) --	1-11,16-17
X	WO 9510518 A1 (BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH), 20 April 1995 (20.04.95) --	1-11,16-17
X	DE 19602853 A1 (BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH), 31 July 1997 (31.07.97) --	1-11,16-17
X	WO 9727192 A1 (BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH), 31 July 1997 (31.07.97) --	1-11,16-17
X	WO 9603404 A1 (BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH), 8 February 1996 (08.02.96) --	1-11,16-17
X	WO 9603405 A1 (BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH), 8 February 1996 (08.02.96) --	1-11,16-17
X	WO 9603402 A1 (BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH), 8 February 1996 (08.02.96) --	1-11,16-17
X	WO 9603403 A1 (BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH), 8 February 1996 (08.02.96) -- -----	1-11,16-17

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/SE99/01402

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 13-15  
because they relate to subject matter not required to be searched by this Authority, namely:  
**A method for treatment of the human or animal body by therapy,  
see rule 39.1.**
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such  
an extent that no meaningful international search can be carried out, specifically:

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

**See extra sheet.**

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is  
restricted to the invention first mentioned in the claims: it is covered by claims Nos.: 1-11, 16-17

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.  
PCT/SE99/01402

The subjects, defined by the problems and their means of solution, as listed below are so different from each other that no technical relationship or interaction can be appreciated to be present so as to form a single general inventive concept.

Invention 1. Claims 1-11 and 16-17 directed to compound I which is useful in the treatment of gastrointestinal inflammatory diseases.

Invention 2. Claims 12 and 18 directed to a pharmaceutical formulation for use in the treatment or prophylaxis of conditions involving infection by *Helicobacter pylori* of the human gastric mucosa, wherein the active ingredient is compound I in combination with at least one antimicrobial agent.

The special technical feature of invention 1 is a novel compound useful in the treatment of gastrointestinal inflammatory diseases. The special technical feature of invention 2 is a combination of a compound I and at least one antimicrobial agent for use in the treatment or prophylaxis of conditions involving infection by *Helicobacter pylori* of the human gastric mucosa.

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

02/12/99

International application No.  
PCT/SE 99/01402

Patent document cited in search report			Publication date	Patent family member(s)	Publication date
EP	0033094	B1	05/08/81	SE 0033094 T3	
				AU 540840 B	06/12/84
				AU 6633781 A	30/07/81
				CA 1167845 A	22/05/84
				DK 25081 A	24/07/81
				ES 498643 A	16/11/82
				FI 810147 A	24/07/81
				GR 72960 A	19/01/84
				HK 94187 A	18/12/87
				IE 50682 B	11/06/86
				IL 61939 A	31/01/86
				JP 56113782 A	07/09/81
				KR 8500240 B	12/03/85
				MY 76087 A	31/12/87
				NO 810198 A	24/07/81
				NZ 196071 A	31/05/84
				OA 6727 A	30/06/82
				PT 72370 A,B	01/02/81
				SG 70887 G	04/03/88
				ZA 8100219 A	27/01/82
US	5574042	A	12/11/96	US 5750699 A	12/05/98
				AT 174596 T	15/01/99
				AU 686115 B	05/02/98
				AU 5024293 A	12/05/94
				CA 2102137 A	03/05/94
				CN 1089947 A	27/07/94
				DE 69322605 D,T	20/05/99
				EP 0596406 A,B	11/05/94
				ES 2125294 T	01/03/99
				HU 66302 A	28/11/94
				HU 211275 B	28/11/95
				HU 9500359 A	28/09/95
				IL 107426 A	13/07/97
				JP 2763036 B	11/06/98
				JP 7300478 A	14/11/95
				MX 9306831 A	31/01/95
				ZA 9308011 A	09/06/94
				JP 7300477 A	14/11/95
WO	9424130	A1	27/10/94	AU 6646094 A	08/11/94
				EP 0695303 A	07/02/96
				JP 8508983 T	24/09/96
				US 5824687 A	20/10/98



**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

02/12/99

International application No.  
PCT/SE 99/01402

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4450164 A	22/05/84	AT 18402 T	15/03/86
		AU 556062 B	23/10/86
		AU 8517882 A	06/01/83
		CA 1248957 A	17/01/89
		DK 284482 A	27/12/82
		EP 0068378 A,B	05/01/83
		SE 0068378 T3	
		ES 513431 A	01/08/83
		FI 73433 B,C	30/06/87
		FI 822266 A	27/12/82
		GR 74924 A	12/07/84
		IE 53324 B	12/10/88
		IL 66141 D	00/00/00
		JP 1718718 C	14/12/92
		JP 4004318 B	27/01/92
		JP 58013584 A	26/01/83
		KR 8801718 B	08/09/88
		MY 62487 A	31/12/87
		NO 822128 A	27/12/82
		NZ 201066 A	16/08/85
		OA 7130 A	31/03/84
		PH 20432 A	05/01/87
		PT 75115 A,B	01/07/82
		ZA 8204516 A	29/02/84
		CA 1202630 A	01/04/86
		US 4507294 A	26/03/85
WO 9418199 A1	18/08/94	AU 678434 B	29/05/97
		AU 6039194 A	29/08/94
		BG 99855 A	30/04/96
		CA 2156078 A	18/08/94
		CN 1119863 A	03/04/96
		CZ 9502088 A	13/12/95
		EP 0683780 A	29/11/95
		FI 953838 A	06/09/95
		HU 72436 A	29/04/96
		IL 108520 A	30/09/97
		JP 8506333 T	09/07/96
		NO 304889 B	01/03/99
		NO 953187 A	14/08/95
		NZ 261579 A	24/03/97
		PL 175932 B	31/03/99
		PL 310171 A	27/11/95
		SG 55184 A	21/12/98
		SK 99795 A	06/12/95
		US 5665730 A	09/09/97
		ZA 9400990 A	17/08/94

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

02/12/99

International application No.  
PCT/SE 99/01402

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9510518 A1	20/04/95	AU 685176 B AU 7937294 A BG 100459 A CA 2173876 A CN 1042633 B CN 1134702 A CZ 9601055 A EP 0723544 A FI 961564 A HU 73851 A HU 9600890 D JP 9503515 T NO 305864 B NO 961414 A NZ 275419 A PL 176424 B PL 313941 A SK 45096 A US 5719161 A	15/01/98 04/05/95 29/11/96 20/04/95 24/03/99 30/10/96 12/06/96 31/07/96 10/04/96 30/09/96 00/00/00 08/04/97 09/08/99 10/06/96 20/12/96 31/05/99 05/08/96 08/01/97 17/02/98
DE 19602853 A1	31/07/97	AU 1545297 A WO 9727193 A	20/08/97 31/07/97
WO 9727192 A1	31/07/97	AU 1445197 A CA 2244770 A DE 19602855 A EP 0882048 A IL 125371 D	20/08/97 31/07/97 31/07/97 09/12/98 00/00/00
WO 9603404 A1	08/02/96	AU 702166 B AU 3166195 A CA 2196076 A EP 0773945 A JP 10505332 T NZ 290819 A	18/02/99 22/02/96 08/02/96 21/05/97 26/05/98 26/06/98
WO 9603405 A1	08/02/96	AU 700730 B AU 3166295 A CA 2196078 A CN 1159806 A CZ 9700226 A EP 0773946 A FI 970330 A HU 77868 A HU 9700024 D JP 10505333 T NO 970341 A NZ 290820 A PL 318262 A SK 197 A	14/01/99 22/02/96 08/02/96 17/09/97 16/07/97 21/05/97 27/01/97 28/09/98 00/00/00 26/05/98 10/02/97 27/05/98 26/05/97 04/06/97
WO 9603402 A1	08/02/96	AU 3221795 A CA 2196075 A EP 0772614 A JP 10505330 T	22/02/96 08/02/96 14/05/97 26/05/98

02/12/99

PCT/SE 99/01402

Form PCT ISA:210 (patent family annex) (July 1992)